https://trial.medpath.com/news/failed-als-drug-biib078-reached-target-but-failed-to-halt-disease-progression-emory-study-reveals 2025-09-10T01:16:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/failed-als-drug-biib078-reached-target-but-failed-to-halt-disease-progression-emory-study-reveals 2025-09-10T01:16:43+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-s-libtayo-combination-therapy-demonstrates-19-4-five-year-survival-rate-in-advanced-lung-cancer 2025-09-10T01:14:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-s-libtayo-combination-therapy-demonstrates-19-4-five-year-survival-rate-in-advanced-lung-cancer 2025-09-10T01:14:36+00:00 hourly 0.9 https://trial.medpath.com/news/paloma-2-study-confirms-efficacy-of-subcutaneous-amivantamab-in-egfr-exon-20-insertion-nsclc 2025-09-10T01:14:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paloma-2-study-confirms-efficacy-of-subcutaneous-amivantamab-in-egfr-exon-20-insertion-nsclc 2025-09-10T01:14:02+00:00 hourly 0.9 https://trial.medpath.com/news/wheeler-bio-partners-with-pharmefex-to-enhance-modularcmc-platform-for-ind-submissions 2025-09-10T01:12:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wheeler-bio-partners-with-pharmefex-to-enhance-modularcmc-platform-for-ind-submissions 2025-09-10T01:12:15+00:00 hourly 0.9 https://trial.medpath.com/news/scribe-therapeutics-demonstrates-breakthrough-crispr-therapy-for-cardiovascular-disease-with-90-lp-a-reduction 2025-09-10T01:09:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scribe-therapeutics-demonstrates-breakthrough-crispr-therapy-for-cardiovascular-disease-with-90-lp-a-reduction 2025-09-10T01:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/nih-recover-tlc-launches-second-round-of-long-covid-clinical-trials-testing-glp-1-drugs-and-other-interventions 2025-09-10T01:09:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-recover-tlc-launches-second-round-of-long-covid-clinical-trials-testing-glp-1-drugs-and-other-interventions 2025-09-10T01:09:13+00:00 hourly 0.9 https://trial.medpath.com/news/analog-pharma-canada-launches-generic-pregnancy-nausea-treatment-in-canadian-market 2025-09-10T01:08:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/analog-pharma-canada-launches-generic-pregnancy-nausea-treatment-in-canadian-market 2025-09-10T01:08:54+00:00 hourly 0.9 https://trial.medpath.com/news/sunobinop-shows-promising-results-in-phase-1b-trial-for-interstitial-cystitis-bladder-pain-syndrome 2025-09-10T01:08:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sunobinop-shows-promising-results-in-phase-1b-trial-for-interstitial-cystitis-bladder-pain-syndrome 2025-09-10T01:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/dz-002-cancer-therapy-advances-to-phase-2-trials-for-pancreatic-cancer-treatment 2025-09-10T01:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dz-002-cancer-therapy-advances-to-phase-2-trials-for-pancreatic-cancer-treatment 2025-09-10T01:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/wearable-devices-secures-patent-for-ai-powered-voice-and-gesture-control-technology 2025-09-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wearable-devices-secures-patent-for-ai-powered-voice-and-gesture-control-technology 2025-09-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nurexone-secures-u-s-patent-for-proprietary-exosome-manufacturing-technology 2025-09-09T21:20:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nurexone-secures-u-s-patent-for-proprietary-exosome-manufacturing-technology 2025-09-09T21:20:02+00:00 hourly 0.9 https://trial.medpath.com/news/pakistan-drug-authority-orders-immediate-recall-of-contaminated-metronidazole-infusion-over-bacterial-endotoxin-contamination 2025-09-09T21:16:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pakistan-drug-authority-orders-immediate-recall-of-contaminated-metronidazole-infusion-over-bacterial-endotoxin-contamination 2025-09-09T21:16:56+00:00 hourly 0.9 https://trial.medpath.com/news/delaware-court-rules-against-novo-nordisk-in-wegovy-patent-case-highlighting-challenges-in-method-of-treatment-claims 2025-09-09T21:16:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delaware-court-rules-against-novo-nordisk-in-wegovy-patent-case-highlighting-challenges-in-method-of-treatment-claims 2025-09-09T21:16:34+00:00 hourly 0.9 https://trial.medpath.com/news/circulating-tumor-dna-monitoring-enables-personalized-immunotherapy-in-limited-stage-small-cell-lung-cancer 2025-09-09T21:16:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circulating-tumor-dna-monitoring-enables-personalized-immunotherapy-in-limited-stage-small-cell-lung-cancer 2025-09-09T21:16:21+00:00 hourly 0.9 https://trial.medpath.com/news/breakwater-study-reveals-ctdna-clearance-predicts-survival-in-braf-v600e-mutant-colorectal-cancer 2025-09-09T21:16:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakwater-study-reveals-ctdna-clearance-predicts-survival-in-braf-v600e-mutant-colorectal-cancer 2025-09-09T21:16:07+00:00 hourly 0.9 https://trial.medpath.com/news/tspo-biomarker-shows-promise-for-early-alzheimer-s-detection-years-before-symptom-onset 2025-09-09T21:15:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tspo-biomarker-shows-promise-for-early-alzheimer-s-detection-years-before-symptom-onset 2025-09-09T21:15:23+00:00 hourly 0.9 https://trial.medpath.com/news/topcon-healthcare-invests-in-senseye-s-ai-powered-mental-health-diagnostic-platform-using-ocular-biomarkers 2025-09-09T21:15:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/topcon-healthcare-invests-in-senseye-s-ai-powered-mental-health-diagnostic-platform-using-ocular-biomarkers 2025-09-09T21:15:07+00:00 hourly 0.9 https://trial.medpath.com/news/lgc-group-opens-100-million-organic-chemistry-synthesis-center-in-canada-to-expand-global-drug-discovery-support 2025-09-09T21:15:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lgc-group-opens-100-million-organic-chemistry-synthesis-center-in-canada-to-expand-global-drug-discovery-support 2025-09-09T21:15:04+00:00 hourly 0.9 https://trial.medpath.com/news/brief-anesthesia-shows-no-short-term-neurodevelopmental-risk-in-infants-under-2-years 2025-09-09T21:14:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brief-anesthesia-shows-no-short-term-neurodevelopmental-risk-in-infants-under-2-years 2025-09-09T21:14:57+00:00 hourly 0.9 https://trial.medpath.com/news/icer-reverses-position-on-glp-1-obesity-drugs-finds-cost-effectiveness-despite-budget-concerns 2025-09-09T21:14:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icer-reverses-position-on-glp-1-obesity-drugs-finds-cost-effectiveness-despite-budget-concerns 2025-09-09T21:14:21+00:00 hourly 0.9 https://trial.medpath.com/news/iregene-therapeutics-raises-40m-series-b-following-fda-fast-track-designation-for-parkinson-s-cell-therapy 2025-09-09T21:10:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iregene-therapeutics-raises-40m-series-b-following-fda-fast-track-designation-for-parkinson-s-cell-therapy 2025-09-09T21:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-s-allergen-blocking-antibodies-achieve-primary-endpoints-in-phase-iii-cat-and-birch-allergy-trials 2025-09-09T21:08:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-s-allergen-blocking-antibodies-achieve-primary-endpoints-in-phase-iii-cat-and-birch-allergy-trials 2025-09-09T21:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/cpap-treatment-reduces-mortality-risk-by-26-in-adults-with-type-2-diabetes-and-sleep-apnea 2025-09-09T17:24:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cpap-treatment-reduces-mortality-risk-by-26-in-adults-with-type-2-diabetes-and-sleep-apnea 2025-09-09T17:24:10+00:00 hourly 0.9 https://trial.medpath.com/news/rion-spins-out-intent-biologics-to-advance-exosome-based-therapies-for-inflammation-and-immunology 2025-09-09T17:19:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rion-spins-out-intent-biologics-to-advance-exosome-based-therapies-for-inflammation-and-immunology 2025-09-09T17:19:57+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-centers-pioneer-decentralized-clinical-trial-models-to-expand-patient-access-nationwide 2025-09-09T17:19:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-centers-pioneer-decentralized-clinical-trial-models-to-expand-patient-access-nationwide 2025-09-09T17:19:15+00:00 hourly 0.9 https://trial.medpath.com/news/bee-sting-inspired-microneedles-deliver-pain-free-drug-therapy-for-neurological-diseases 2025-09-09T17:19:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bee-sting-inspired-microneedles-deliver-pain-free-drug-therapy-for-neurological-diseases 2025-09-09T17:19:10+00:00 hourly 0.9 https://trial.medpath.com/news/nkgen-biotech-completes-16-9m-acquisition-of-nkmax-gains-control-of-nk-cell-manufacturing 2025-09-09T17:19:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nkgen-biotech-completes-16-9m-acquisition-of-nkmax-gains-control-of-nk-cell-manufacturing 2025-09-09T17:19:07+00:00 hourly 0.9 https://trial.medpath.com/news/immunic-secures-fifth-us-patent-for-multiple-sclerosis-drug-vidofludimus-calcium-extending-protection-through-2041 2025-09-09T17:18:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunic-secures-fifth-us-patent-for-multiple-sclerosis-drug-vidofludimus-calcium-extending-protection-through-2041 2025-09-09T17:18:13+00:00 hourly 0.9 https://trial.medpath.com/news/cho-plus-secures-u-s-patent-for-engineered-yeast-cell-technology-to-boost-protein-production 2025-09-09T17:18:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cho-plus-secures-u-s-patent-for-engineered-yeast-cell-technology-to-boost-protein-production 2025-09-09T17:18:11+00:00 hourly 0.9 https://trial.medpath.com/news/kytopen-and-bluewhale-bio-partner-to-accelerate-non-viral-cell-therapy-manufacturing 2025-09-09T17:18:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kytopen-and-bluewhale-bio-partner-to-accelerate-non-viral-cell-therapy-manufacturing 2025-09-09T17:18:03+00:00 hourly 0.9 https://trial.medpath.com/news/viral-immunotherapy-can-2409-demonstrates-24-5-month-median-survival-in-checkpoint-inhibitor-resistant-nsclc 2025-09-09T17:17:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viral-immunotherapy-can-2409-demonstrates-24-5-month-median-survival-in-checkpoint-inhibitor-resistant-nsclc 2025-09-09T17:17:03+00:00 hourly 0.9 https://trial.medpath.com/news/mit-researchers-develop-bottlebrush-polymer-technology-to-dramatically-increase-cancer-drug-payload-delivery 2025-09-09T17:16:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mit-researchers-develop-bottlebrush-polymer-technology-to-dramatically-increase-cancer-drug-payload-delivery 2025-09-09T17:16:58+00:00 hourly 0.9 https://trial.medpath.com/news/hope-biosciences-stem-cell-therapy-achieves-primary-endpoint-in-phase-2-multiple-sclerosis-trial 2025-09-09T17:16:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hope-biosciences-stem-cell-therapy-achieves-primary-endpoint-in-phase-2-multiple-sclerosis-trial 2025-09-09T17:16:40+00:00 hourly 0.9 https://trial.medpath.com/news/linusbio-develops-first-hair-based-biomarker-for-als-detection-using-copper-patterns 2025-09-09T17:16:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/linusbio-develops-first-hair-based-biomarker-for-als-detection-using-copper-patterns 2025-09-09T17:16:16+00:00 hourly 0.9 https://trial.medpath.com/news/vicero-appoints-dr-han-myint-as-chief-medical-officer-to-advance-vincobody-immunotherapy-pipeline 2025-09-09T17:15:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vicero-appoints-dr-han-myint-as-chief-medical-officer-to-advance-vincobody-immunotherapy-pipeline 2025-09-09T17:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/liscure-biosciences-achieves-world-s-first-fda-ndi-notification-for-hair-health-probiotic-mobiome-r 2025-09-09T17:15:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liscure-biosciences-achieves-world-s-first-fda-ndi-notification-for-hair-health-probiotic-mobiome-r 2025-09-09T17:15:25+00:00 hourly 0.9 https://trial.medpath.com/news/oncoc4-and-biontech-advance-pivotal-phase-3-trial-of-next-generation-ctla-4-antibody-gotistobart-in-squamous-nsclc 2025-09-09T17:15:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncoc4-and-biontech-advance-pivotal-phase-3-trial-of-next-generation-ctla-4-antibody-gotistobart-in-squamous-nsclc 2025-09-09T17:15:12+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-acquires-elutia-s-bioenvelope-business-for-88-million-fueling-breast-reconstruction-pipeline 2025-09-09T17:13:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-scientific-acquires-elutia-s-bioenvelope-business-for-88-million-fueling-breast-reconstruction-pipeline 2025-09-09T17:13:51+00:00 hourly 0.9 https://trial.medpath.com/news/insitro-and-eli-lilly-partner-to-develop-ai-powered-admet-prediction-models-for-small-molecule-drug-discovery 2025-09-09T17:13:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insitro-and-eli-lilly-partner-to-develop-ai-powered-admet-prediction-models-for-small-molecule-drug-discovery 2025-09-09T17:13:41+00:00 hourly 0.9 https://trial.medpath.com/news/xtalpi-s-ai-designed-prmt5-inhibitor-pep08-receives-clinical-trial-approvals-for-solid-tumors 2025-09-09T17:13:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xtalpi-s-ai-designed-prmt5-inhibitor-pep08-receives-clinical-trial-approvals-for-solid-tumors 2025-09-09T17:13:36+00:00 hourly 0.9 https://trial.medpath.com/news/ionctura-expands-roginolisib-clinical-trials-to-us-market-with-multi-cancer-strategy 2025-09-09T17:13:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ionctura-expands-roginolisib-clinical-trials-to-us-market-with-multi-cancer-strategy 2025-09-09T17:13:27+00:00 hourly 0.9 https://trial.medpath.com/news/cellcentric-completes-enrollment-for-inobrodib-dose-optimization-study-in-multiple-myeloma 2025-09-09T17:13:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellcentric-completes-enrollment-for-inobrodib-dose-optimization-study-in-multiple-myeloma 2025-09-09T17:13:16+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-validates-purist-algorithm-for-personalized-pancreatic-cancer-treatment-selection-in-largest-real-world-study 2025-09-09T17:13:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempus-validates-purist-algorithm-for-personalized-pancreatic-cancer-treatment-selection-in-largest-real-world-study 2025-09-09T17:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/teva-s-emrusolmin-receives-fda-fast-track-designation-for-multiple-system-atrophy-treatment 2025-09-09T17:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teva-s-emrusolmin-receives-fda-fast-track-designation-for-multiple-system-atrophy-treatment 2025-09-09T17:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-ns-229-jak1-inhibitor-for-rare-autoimmune-disease-egpa 2025-09-09T17:12:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-ns-229-jak1-inhibitor-for-rare-autoimmune-disease-egpa 2025-09-09T17:12:57+00:00 hourly 0.9 https://trial.medpath.com/news/ridge-biotechnologies-emerges-from-stealth-with-25m-seed-funding-for-ai-driven-enzyme-design-platform 2025-09-09T17:12:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ridge-biotechnologies-emerges-from-stealth-with-25m-seed-funding-for-ai-driven-enzyme-design-platform 2025-09-09T17:12:49+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-confirms-inotuzumab-ozogamicin-efficacy-in-indian-patients-with-relapsed-refractory-b-cell-all 2025-09-09T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-confirms-inotuzumab-ozogamicin-efficacy-in-indian-patients-with-relapsed-refractory-b-cell-all 2025-09-09T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alembic-pharmaceuticals-secures-fda-approval-for-phytonadione-injectable-emulsion-in-44-million-market 2025-09-09T13:10:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alembic-pharmaceuticals-secures-fda-approval-for-phytonadione-injectable-emulsion-in-44-million-market 2025-09-09T13:10:43+00:00 hourly 0.9 https://trial.medpath.com/news/pheon-therapeutics-appoints-google-ventures-dr-samuel-blackman-to-board-as-adc-programs-advance 2025-09-09T13:10:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pheon-therapeutics-appoints-google-ventures-dr-samuel-blackman-to-board-as-adc-programs-advance 2025-09-09T13:10:17+00:00 hourly 0.9 https://trial.medpath.com/news/integra-therapeutics-raises-eur10-7-million-to-advance-ficat-gene-writing-platform-and-car-t-therapies 2025-09-09T13:10:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/integra-therapeutics-raises-eur10-7-million-to-advance-ficat-gene-writing-platform-and-car-t-therapies 2025-09-09T13:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/cambridge-scientists-develop-ph-responsive-artificial-cartilage-for-targeted-arthritis-drug-delivery 2025-09-09T13:08:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cambridge-scientists-develop-ph-responsive-artificial-cartilage-for-targeted-arthritis-drug-delivery 2025-09-09T13:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-updated-guidance-for-therapeutic-protein-biosimilar-development-with-enhanced-analytical-requirements 2025-09-09T13:08:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-updated-guidance-for-therapeutic-protein-biosimilar-development-with-enhanced-analytical-requirements 2025-09-09T13:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/connecta-therapeutics-advances-first-in-class-neuroplasticity-modulator-cth120-to-phase-ii-for-pediatric-fragile-x-syndrome 2025-09-09T13:08:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/connecta-therapeutics-advances-first-in-class-neuroplasticity-modulator-cth120-to-phase-ii-for-pediatric-fragile-x-syndrome 2025-09-09T13:08:41+00:00 hourly 0.9 https://trial.medpath.com/news/surgical-resection-combined-with-egfr-tki-shows-promising-results-in-metastatic-nsclc-trial 2025-09-09T13:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/surgical-resection-combined-with-egfr-tki-shows-promising-results-in-metastatic-nsclc-trial 2025-09-09T13:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-launches-tunelab-ai-platform-to-democratize-drug-discovery-for-biotech-companies 2025-09-09T13:08:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-launches-tunelab-ai-platform-to-democratize-drug-discovery-for-biotech-companies 2025-09-09T13:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/mirum-pharmaceuticals-completes-enrollment-in-phase-2b-vistas-study-for-primary-sclerosing-cholangitis-treatment 2025-09-09T13:08:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mirum-pharmaceuticals-completes-enrollment-in-phase-2b-vistas-study-for-primary-sclerosing-cholangitis-treatment 2025-09-09T13:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/adcs-transform-nsclc-treatment-landscape-with-multiple-fda-approvals-and-expanding-clinical-applications 2025-09-09T10:53:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adcs-transform-nsclc-treatment-landscape-with-multiple-fda-approvals-and-expanding-clinical-applications 2025-09-09T10:53:38+00:00 hourly 0.9 https://trial.medpath.com/news/tevogen-s-tvgn-489-t-cell-therapy-achieves-9-11-billion-valuation-following-successful-covid-19-trial 2025-09-09T09:13:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tevogen-s-tvgn-489-t-cell-therapy-achieves-9-11-billion-valuation-following-successful-covid-19-trial 2025-09-09T09:13:23+00:00 hourly 0.9 https://trial.medpath.com/news/matica-biotechnology-partners-with-cirsium-biosciences-to-advance-plant-based-aav-manufacturing-for-gene-therapy 2025-09-09T09:12:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/matica-biotechnology-partners-with-cirsium-biosciences-to-advance-plant-based-aav-manufacturing-for-gene-therapy 2025-09-09T09:12:57+00:00 hourly 0.9 https://trial.medpath.com/news/alchemab-therapeutics-initiates-phase-1-trial-of-atlx-1282-and-secures-32-million-series-a-extension 2025-09-09T09:11:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alchemab-therapeutics-initiates-phase-1-trial-of-atlx-1282-and-secures-32-million-series-a-extension 2025-09-09T09:11:34+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-recruits-former-fda-cell-and-gene-therapy-official-rachael-anatol-to-lead-genetic-medicine-strategy 2025-09-09T09:10:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-recruits-former-fda-cell-and-gene-therapy-official-rachael-anatol-to-lead-genetic-medicine-strategy 2025-09-09T09:10:46+00:00 hourly 0.9 https://trial.medpath.com/news/remedium-bio-partners-with-eli-lilly-to-develop-gene-therapies-for-obesity-and-type-2-diabetes 2025-09-09T09:10:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remedium-bio-partners-with-eli-lilly-to-develop-gene-therapies-for-obesity-and-type-2-diabetes 2025-09-09T09:10:43+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-acquires-tourmaline-bio-for-1-4-billion-to-advance-anti-inflammatory-cardiovascular-therapy 2025-09-09T09:10:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-acquires-tourmaline-bio-for-1-4-billion-to-advance-anti-inflammatory-cardiovascular-therapy 2025-09-09T09:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-resolves-patent-dispute-with-regeneron-clearing-path-for-eylea-biosimilar-launch-by-2026 2025-09-09T09:09:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sandoz-resolves-patent-dispute-with-regeneron-clearing-path-for-eylea-biosimilar-launch-by-2026 2025-09-09T09:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-secures-patent-settlement-with-regeneron-clears-path-for-aflibercept-biosimilar-launch-by-end-of-2026 2025-09-09T09:09:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sandoz-secures-patent-settlement-with-regeneron-clears-path-for-aflibercept-biosimilar-launch-by-end-of-2026 2025-09-09T09:09:24+00:00 hourly 0.9 https://trial.medpath.com/news/strides-pharma-partners-with-kenox-to-expand-us-nasal-spray-portfolio 2025-09-09T09:09:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strides-pharma-partners-with-kenox-to-expand-us-nasal-spray-portfolio 2025-09-09T09:09:18+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-acquires-tourmaline-bio-for-1-4-billion-to-strengthen-cardiovascular-pipeline-with-pacibekitug 2025-09-09T09:09:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-acquires-tourmaline-bio-for-1-4-billion-to-strengthen-cardiovascular-pipeline-with-pacibekitug 2025-09-09T09:09:13+00:00 hourly 0.9 https://trial.medpath.com/news/synthetic-peptide-pep19-shows-promise-in-reducing-visceral-fat-and-improving-sleep-in-obese-adults 2025-09-09T09:09:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synthetic-peptide-pep19-shows-promise-in-reducing-visceral-fat-and-improving-sleep-in-obese-adults 2025-09-09T09:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/tolerance-bio-partners-with-zipcode-bio-to-develop-targeted-thymus-therapeutics-for-immune-aging 2025-09-09T06:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tolerance-bio-partners-with-zipcode-bio-to-develop-targeted-thymus-therapeutics-for-immune-aging 2025-09-09T06:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/dianthus-therapeutics-closes-upsized-288-million-public-offering-to-advance-complement-therapeutics-pipeline 2025-09-09T06:45:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dianthus-therapeutics-closes-upsized-288-million-public-offering-to-advance-complement-therapeutics-pipeline 2025-09-09T06:45:05+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-reduces-long-covid-risk-by-64-in-overweight-adults-uk-study-finds 2025-09-09T06:42:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metformin-reduces-long-covid-risk-by-64-in-overweight-adults-uk-study-finds 2025-09-09T06:42:35+00:00 hourly 0.9 https://trial.medpath.com/news/photonpharma-secures-u-s-patent-for-novel-cancer-immunotherapy-using-photochemically-inactivated-tumor-cells 2025-09-09T06:41:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/photonpharma-secures-u-s-patent-for-novel-cancer-immunotherapy-using-photochemically-inactivated-tumor-cells 2025-09-09T06:41:56+00:00 hourly 0.9 https://trial.medpath.com/news/pressure-enabled-drug-delivery-system-enhances-nelitolimod-efficacy-in-liver-tumors 2025-09-09T06:41:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pressure-enabled-drug-delivery-system-enhances-nelitolimod-efficacy-in-liver-tumors 2025-09-09T06:41:26+00:00 hourly 0.9 https://trial.medpath.com/news/astellas-restructures-leadership-team-with-digital-and-transformation-functions-integration 2025-09-09T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astellas-restructures-leadership-team-with-digital-and-transformation-functions-integration 2025-09-09T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/amo-pharma-launches-largest-ever-clinical-trial-for-rare-heart-condition-arvc-with-gsk3b-inhibitor-amo-02 2025-09-09T04:07:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amo-pharma-launches-largest-ever-clinical-trial-for-rare-heart-condition-arvc-with-gsk3b-inhibitor-amo-02 2025-09-09T04:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/four-jak-inhibitors-now-enable-personalized-myelofibrosis-treatment-approaches 2025-09-09T04:07:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/four-jak-inhibitors-now-enable-personalized-myelofibrosis-treatment-approaches 2025-09-09T04:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/seladelpar-shows-promise-in-stabilizing-liver-stiffness-in-primary-biliary-cholangitis-patients 2025-09-09T02:46:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seladelpar-shows-promise-in-stabilizing-liver-stiffness-in-primary-biliary-cholangitis-patients 2025-09-09T02:46:19+00:00 hourly 0.9 https://trial.medpath.com/news/daiichi-sankyo-expands-global-research-network-with-new-san-diego-institute-and-154m-shanghai-adc-manufacturing-facility 2025-09-09T01:44:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daiichi-sankyo-expands-global-research-network-with-new-san-diego-institute-and-154m-shanghai-adc-manufacturing-facility 2025-09-09T01:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/sound-wave-innovation-and-sumitomo-heavy-industries-partner-to-advance-lipus-brain-device-for-alzheimer-s-treatment 2025-09-09T01:08:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sound-wave-innovation-and-sumitomo-heavy-industries-partner-to-advance-lipus-brain-device-for-alzheimer-s-treatment 2025-09-09T01:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/immix-biopharma-secures-strategic-investment-from-goose-capital-for-al-amyloidosis-car-t-therapy 2025-09-09T01:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immix-biopharma-secures-strategic-investment-from-goose-capital-for-al-amyloidosis-car-t-therapy 2025-09-09T01:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-bristol-myers-bispecific-antibody-achieves-76-3-response-rate-in-small-cell-lung-cancer-phase-ii-trial 2025-09-08T21:17:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biontech-bristol-myers-bispecific-antibody-achieves-76-3-response-rate-in-small-cell-lung-cancer-phase-ii-trial 2025-09-08T21:17:24+00:00 hourly 0.9 https://trial.medpath.com/news/uc-san-diego-researchers-develop-non-hormonal-hydrogel-treatment-for-menopausal-vaginal-symptoms 2025-09-08T21:15:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-san-diego-researchers-develop-non-hormonal-hydrogel-treatment-for-menopausal-vaginal-symptoms 2025-09-08T21:15:03+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-data-shows-dora-insomnia-drugs-have-minimal-abuse-potential-compared-to-traditional-sleep-medications 2025-09-08T21:13:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-data-shows-dora-insomnia-drugs-have-minimal-abuse-potential-compared-to-traditional-sleep-medications 2025-09-08T21:13:58+00:00 hourly 0.9 https://trial.medpath.com/news/scotland-approves-linzagolix-for-endometriosis-treatment-expanding-access-across-uk 2025-09-08T21:13:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scotland-approves-linzagolix-for-endometriosis-treatment-expanding-access-across-uk 2025-09-08T21:13:53+00:00 hourly 0.9 https://trial.medpath.com/news/aavivo-advances-in-vivo-car-t-platform-with-pace-technology-for-precision-gene-delivery 2025-09-08T21:13:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aavivo-advances-in-vivo-car-t-platform-with-pace-technology-for-precision-gene-delivery 2025-09-08T21:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/apollo-trial-establishes-new-standard-for-high-risk-acute-promyelocytic-leukemia-treatment 2025-09-08T21:12:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apollo-trial-establishes-new-standard-for-high-risk-acute-promyelocytic-leukemia-treatment 2025-09-08T21:12:30+00:00 hourly 0.9 https://trial.medpath.com/news/phanes-therapeutics-doses-first-biliary-tract-cancer-patient-with-novel-bispecific-antibody-spevatamig 2025-09-08T21:11:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phanes-therapeutics-doses-first-biliary-tract-cancer-patient-with-novel-bispecific-antibody-spevatamig 2025-09-08T21:11:45+00:00 hourly 0.9 https://trial.medpath.com/news/dianthus-therapeutics-claseprubart-meets-all-endpoints-in-phase-2-myasthenia-gravis-trial 2025-09-08T21:11:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dianthus-therapeutics-claseprubart-meets-all-endpoints-in-phase-2-myasthenia-gravis-trial 2025-09-08T21:11:20+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-biontech-covid-booster-shows-strong-immune-response-in-late-stage-study 2025-09-08T21:09:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-biontech-covid-booster-shows-strong-immune-response-in-late-stage-study 2025-09-08T21:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/azacitidine-ruxolitinib-combination-shows-promise-for-advanced-myeloproliferative-neoplasms 2025-09-08T17:16:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/azacitidine-ruxolitinib-combination-shows-promise-for-advanced-myeloproliferative-neoplasms 2025-09-08T17:16:07+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-and-bristol-myers-squibb-report-promising-phase-2-results-for-pumitamig-in-extensive-stage-small-cell-lung-cancer 2025-09-08T17:16:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biontech-and-bristol-myers-squibb-report-promising-phase-2-results-for-pumitamig-in-extensive-stage-small-cell-lung-cancer 2025-09-08T17:16:01+00:00 hourly 0.9 https://trial.medpath.com/news/cs-diagnostics-submits-patent-application-for-cs-protect-hydrogel-organ-spacer-device 2025-09-08T17:15:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cs-diagnostics-submits-patent-application-for-cs-protect-hydrogel-organ-spacer-device 2025-09-08T17:15:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-complete-response-letter-for-saol-s-sl1009-treatment-for-rare-pediatric-mitochondrial-disease 2025-09-08T17:13:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-complete-response-letter-for-saol-s-sl1009-treatment-for-rare-pediatric-mitochondrial-disease 2025-09-08T17:13:27+00:00 hourly 0.9 https://trial.medpath.com/news/kbi-biopharma-partners-with-infinimmune-to-advance-human-first-antibody-manufacturing-for-atopic-dermatitis 2025-09-08T17:13:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kbi-biopharma-partners-with-infinimmune-to-advance-human-first-antibody-manufacturing-for-atopic-dermatitis 2025-09-08T17:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/beyond-air-s-neuronos-receives-fda-orphan-drug-designation-for-glioblastoma-therapy-ba-101 2025-09-08T17:12:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyond-air-s-neuronos-receives-fda-orphan-drug-designation-for-glioblastoma-therapy-ba-101 2025-09-08T17:12:32+00:00 hourly 0.9 https://trial.medpath.com/news/anktiva-reverses-lymphopenia-and-extends-survival-in-checkpoint-inhibitor-resistant-lung-cancer 2025-09-08T17:12:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anktiva-reverses-lymphopenia-and-extends-survival-in-checkpoint-inhibitor-resistant-lung-cancer 2025-09-08T17:12:01+00:00 hourly 0.9 https://trial.medpath.com/news/icecure-s-prosense-cryoablation-system-achieves-superior-results-in-early-stage-breast-cancer-trial 2025-09-08T17:11:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icecure-s-prosense-cryoablation-system-achieves-superior-results-in-early-stage-breast-cancer-trial 2025-09-08T17:11:54+00:00 hourly 0.9 https://trial.medpath.com/news/cormedix-makes-5-million-strategic-investment-in-talphera-s-phase-3-anticoagulant-program 2025-09-08T17:11:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cormedix-makes-5-million-strategic-investment-in-talphera-s-phase-3-anticoagulant-program 2025-09-08T17:11:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-clinical-trial-for-pig-kidney-transplants-as-second-patient-achieves-dialysis-free-life 2025-09-08T17:07:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-clinical-trial-for-pig-kidney-transplants-as-second-patient-achieves-dialysis-free-life 2025-09-08T17:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-develop-3d-printing-glue-gun-for-real-time-bone-graft-surgery 2025-09-08T13:24:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-develop-3d-printing-glue-gun-for-real-time-bone-graft-surgery 2025-09-08T13:24:11+00:00 hourly 0.9 https://trial.medpath.com/news/atom-therapeutics-urat1-inhibitor-lingdolinurad-meets-primary-endpoint-in-phase-2b-3-chronic-gout-trial 2025-09-08T13:20:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atom-therapeutics-urat1-inhibitor-lingdolinurad-meets-primary-endpoint-in-phase-2b-3-chronic-gout-trial 2025-09-08T13:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/hypofractionated-radiotherapy-reduces-treatment-time-and-toxicity-while-maintaining-survival-in-limited-stage-small-cell-lung-cancer 2025-09-08T13:19:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hypofractionated-radiotherapy-reduces-treatment-time-and-toxicity-while-maintaining-survival-in-limited-stage-small-cell-lung-cancer 2025-09-08T13:19:07+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-s-first-in-class-allergen-blocking-antibodies-show-52-reduction-in-cat-allergy-symptoms-in-phase-3-trials 2025-09-08T13:16:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-s-first-in-class-allergen-blocking-antibodies-show-52-reduction-in-cat-allergy-symptoms-in-phase-3-trials 2025-09-08T13:16:44+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-ea5181-trial-shows-no-survival-benefit-for-concurrent-durvalumab-with-chemoradiotherapy-in-stage-iii-nsclc 2025-09-08T13:16:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-ea5181-trial-shows-no-survival-benefit-for-concurrent-durvalumab-with-chemoradiotherapy-in-stage-iii-nsclc 2025-09-08T13:16:41+00:00 hourly 0.9 https://trial.medpath.com/news/charm-therapeutics-appoints-dr-erkut-bahceci-as-cmo-to-lead-next-generation-menin-inhibitor-development 2025-09-08T13:15:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/charm-therapeutics-appoints-dr-erkut-bahceci-as-cmo-to-lead-next-generation-menin-inhibitor-development 2025-09-08T13:15:44+00:00 hourly 0.9 https://trial.medpath.com/news/tigulixostat-shows-superior-efficacy-over-febuxostat-in-phase-2-gout-trial 2025-09-08T13:14:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tigulixostat-shows-superior-efficacy-over-febuxostat-in-phase-2-gout-trial 2025-09-08T13:14:24+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-university-receives-double-digit-million-nih-grant-for-phase-ii-trial-of-tiprelestat-in-pulmonary-arterial-hypertension 2025-09-08T13:14:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-university-receives-double-digit-million-nih-grant-for-phase-ii-trial-of-tiprelestat-in-pulmonary-arterial-hypertension 2025-09-08T13:14:18+00:00 hourly 0.9 https://trial.medpath.com/news/locate-bio-receives-fda-ide-approval-to-expand-restore-clinical-study-of-ldgraft-bone-graft-substitute-to-us 2025-09-08T13:13:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/locate-bio-receives-fda-ide-approval-to-expand-restore-clinical-study-of-ldgraft-bone-graft-substitute-to-us 2025-09-08T13:13:20+00:00 hourly 0.9 https://trial.medpath.com/news/dea-licensing-contradictions-block-fda-approved-cannabis-research-while-va-seeks-foreign-imports 2025-09-08T13:13:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dea-licensing-contradictions-block-fda-approved-cannabis-research-while-va-seeks-foreign-imports 2025-09-08T13:13:11+00:00 hourly 0.9 https://trial.medpath.com/news/nrg-therapeutics-raises-67-million-to-advance-novel-mitochondrial-targeting-therapy-for-parkinson-s-and-als 2025-09-08T13:12:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nrg-therapeutics-raises-67-million-to-advance-novel-mitochondrial-targeting-therapy-for-parkinson-s-and-als 2025-09-08T13:12:06+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-pointer-trial-demonstrates-lifestyle-interventions-can-prevent-cognitive-decline-in-diverse-populations 2025-09-08T10:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-pointer-trial-demonstrates-lifestyle-interventions-can-prevent-cognitive-decline-in-diverse-populations 2025-09-08T10:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/sirnaomics-secures-hkd-138-million-strategic-investment-from-bloomage-biotech-for-rnai-therapeutics-development 2025-09-08T09:12:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sirnaomics-secures-hkd-138-million-strategic-investment-from-bloomage-biotech-for-rnai-therapeutics-development 2025-09-08T09:12:21+00:00 hourly 0.9 https://trial.medpath.com/news/toolgen-files-patent-infringement-lawsuit-against-lonza-over-crispr-technology-used-in-casgevy-production 2025-09-08T09:12:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/toolgen-files-patent-infringement-lawsuit-against-lonza-over-crispr-technology-used-in-casgevy-production 2025-09-08T09:12:18+00:00 hourly 0.9 https://trial.medpath.com/news/servier-acquires-ker-0193-for-450m-to-target-fragile-x-syndrome-marking-first-neurology-asset 2025-09-08T09:11:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/servier-acquires-ker-0193-for-450m-to-target-fragile-x-syndrome-marking-first-neurology-asset 2025-09-08T09:11:45+00:00 hourly 0.9 https://trial.medpath.com/news/innocare-s-btk-inhibitor-orelabrutinib-gains-singapore-approval-for-relapsed-refractory-marginal-zone-lymphoma 2025-09-08T09:11:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innocare-s-btk-inhibitor-orelabrutinib-gains-singapore-approval-for-relapsed-refractory-marginal-zone-lymphoma 2025-09-08T09:11:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-launches-fast-track-review-program-for-nicotine-pouches-under-trump-administration-pressure 2025-09-08T09:10:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-launches-fast-track-review-program-for-nicotine-pouches-under-trump-administration-pressure 2025-09-08T09:10:40+00:00 hourly 0.9 https://trial.medpath.com/news/mankind-pharma-receives-cdsco-approval-for-phase-1-trial-of-jak-inhibitor-mkp11093-for-autoimmune-disorders 2025-09-08T09:10:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mankind-pharma-receives-cdsco-approval-for-phase-1-trial-of-jak-inhibitor-mkp11093-for-autoimmune-disorders 2025-09-08T09:10:26+00:00 hourly 0.9 https://trial.medpath.com/news/a2-bio-to-present-early-clinical-data-from-logic-gated-car-t-therapy-trials-at-sitc-2025 2025-09-08T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a2-bio-to-present-early-clinical-data-from-logic-gated-car-t-therapy-trials-at-sitc-2025 2025-09-08T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/epigenic-therapeutics-secures-60-million-series-b-to-advance-epigenetic-therapies-for-hepatitis-b-and-cholesterol 2025-09-08T06:12:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epigenic-therapeutics-secures-60-million-series-b-to-advance-epigenetic-therapies-for-hepatitis-b-and-cholesterol 2025-09-08T06:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/new-zealand-passes-medicines-amendment-act-to-accelerate-drug-approvals-through-international-recognition 2025-09-08T01:08:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-zealand-passes-medicines-amendment-act-to-accelerate-drug-approvals-through-international-recognition 2025-09-08T01:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/aumolertinib-plus-anlotinib-shows-promise-for-untreated-egfr-mutant-nsclc-with-cns-metastases 2025-09-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aumolertinib-plus-anlotinib-shows-promise-for-untreated-egfr-mutant-nsclc-with-cns-metastases 2025-09-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aspirin-therapy-shows-no-significant-benefit-for-chronic-rhinosinusitis-with-nasal-polyps-in-randomized-trial 2025-09-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspirin-therapy-shows-no-significant-benefit-for-chronic-rhinosinusitis-with-nasal-polyps-in-randomized-trial 2025-09-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-receives-fda-approval-for-eydenzelt-first-aflibercept-biosimilar-for-retinal-diseases 2025-09-07T21:09:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celltrion-receives-fda-approval-for-eydenzelt-first-aflibercept-biosimilar-for-retinal-diseases 2025-09-07T21:09:08+00:00 hourly 0.9 https://trial.medpath.com/news/precigen-s-papzimeos-becomes-first-fda-approved-treatment-for-rare-respiratory-disease 2025-09-07T21:08:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precigen-s-papzimeos-becomes-first-fda-approved-treatment-for-rare-respiratory-disease 2025-09-07T21:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-stocks-surge-following-acip-rsv-vaccine-recommendations-and-gilead-pipeline-updates 2025-09-07T17:10:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-stocks-surge-following-acip-rsv-vaccine-recommendations-and-gilead-pipeline-updates 2025-09-07T17:10:03+00:00 hourly 0.9 https://trial.medpath.com/news/junshi-biosciences-il-17a-inhibitor-js005-meets-primary-endpoints-in-phase-3-psoriasis-trial 2025-09-07T17:09:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/junshi-biosciences-il-17a-inhibitor-js005-meets-primary-endpoints-in-phase-3-psoriasis-trial 2025-09-07T17:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/abbv-706-shows-promising-58-response-rate-in-relapsed-small-cell-lung-cancer-phase-i-trial 2025-09-07T17:09:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbv-706-shows-promising-58-response-rate-in-relapsed-small-cell-lung-cancer-phase-i-trial 2025-09-07T17:09:04+00:00 hourly 0.9 https://trial.medpath.com/news/adjuvant-crizotinib-fails-to-improve-disease-free-survival-in-early-stage-alk-positive-nsclc 2025-09-07T13:13:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adjuvant-crizotinib-fails-to-improve-disease-free-survival-in-early-stage-alk-positive-nsclc 2025-09-07T13:13:53+00:00 hourly 0.9 https://trial.medpath.com/news/summit-therapeutics-ivonescimab-shows-regional-efficacy-disparities-in-phase-iii-lung-cancer-trial 2025-09-07T13:11:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/summit-therapeutics-ivonescimab-shows-regional-efficacy-disparities-in-phase-iii-lung-cancer-trial 2025-09-07T13:11:02+00:00 hourly 0.9 https://trial.medpath.com/news/genesight-pharmacogenomic-test-demonstrates-significant-clinical-benefits-for-major-depressive-disorder-treatment 2025-09-07T03:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genesight-pharmacogenomic-test-demonstrates-significant-clinical-benefits-for-major-depressive-disorder-treatment 2025-09-07T03:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-amlitelimab-shows-significant-efficacy-in-phase-3-atopic-dermatitis-trial 2025-09-07T02:40:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-s-amlitelimab-shows-significant-efficacy-in-phase-3-atopic-dermatitis-trial 2025-09-07T02:40:51+00:00 hourly 0.9 https://trial.medpath.com/news/adagene-s-masked-anti-ctla-4-therapy-adg126-shows-30-response-rate-in-treatment-resistant-colorectal-cancer 2025-09-07T01:15:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adagene-s-masked-anti-ctla-4-therapy-adg126-shows-30-response-rate-in-treatment-resistant-colorectal-cancer 2025-09-07T01:15:22+00:00 hourly 0.9 https://trial.medpath.com/news/checkmate-77t-trial-shows-perioperative-nivolumab-preserves-quality-of-life-in-resectable-nsclc 2025-09-07T01:13:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/checkmate-77t-trial-shows-perioperative-nivolumab-preserves-quality-of-life-in-resectable-nsclc 2025-09-07T01:13:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warning-to-amneal-pharmaceuticals-over-contaminated-iv-bags-in-sterile-injectable-production 2025-09-07T01:12:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-warning-to-amneal-pharmaceuticals-over-contaminated-iv-bags-in-sterile-injectable-production 2025-09-07T01:12:40+00:00 hourly 0.9 https://trial.medpath.com/news/ai-lung-cancer-risk-model-sybil-validated-in-predominantly-black-patient-population 2025-09-07T01:10:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-lung-cancer-risk-model-sybil-validated-in-predominantly-black-patient-population 2025-09-07T01:10:49+00:00 hourly 0.9 https://trial.medpath.com/news/theratechnologies-launches-egrifta-wr-first-weekly-formulation-for-hiv-associated-lipodystrophy 2025-09-07T01:10:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theratechnologies-launches-egrifta-wr-first-weekly-formulation-for-hiv-associated-lipodystrophy 2025-09-07T01:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/h2-global-group-receives-european-regulatory-approval-for-first-hydrogen-inhalation-therapy-trial-in-alzheimer-s-disease 2025-09-06T21:13:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/h2-global-group-receives-european-regulatory-approval-for-first-hydrogen-inhalation-therapy-trial-in-alzheimer-s-disease 2025-09-06T21:13:55+00:00 hourly 0.9 https://trial.medpath.com/news/sprintray-acquires-envisiontec-dental-portfolio-following-desktop-metal-bankruptcy 2025-09-06T21:11:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sprintray-acquires-envisiontec-dental-portfolio-following-desktop-metal-bankruptcy 2025-09-06T21:11:47+00:00 hourly 0.9 https://trial.medpath.com/news/nuvation-bio-surges-14-9-on-analyst-upgrades-and-oncology-pipeline-progress 2025-09-06T21:10:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuvation-bio-surges-14-9-on-analyst-upgrades-and-oncology-pipeline-progress 2025-09-06T21:10:46+00:00 hourly 0.9 https://trial.medpath.com/news/md-anderson-researchers-advance-cancer-treatment-with-novel-pan-kras-inhibitor-and-precision-therapies 2025-09-06T17:14:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/md-anderson-researchers-advance-cancer-treatment-with-novel-pan-kras-inhibitor-and-precision-therapies 2025-09-06T17:14:51+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-s-cemdisiran-shows-positive-phase-3-results-driving-investment-interest-despite-mixed-market-performance 2025-09-06T17:12:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-s-cemdisiran-shows-positive-phase-3-results-driving-investment-interest-despite-mixed-market-performance 2025-09-06T17:12:36+00:00 hourly 0.9 https://trial.medpath.com/news/ultrasound-ai-secures-patent-for-ai-driven-clinical-value-determination-from-medical-images 2025-09-06T17:11:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultrasound-ai-secures-patent-for-ai-driven-clinical-value-determination-from-medical-images 2025-09-06T17:11:56+00:00 hourly 0.9 https://trial.medpath.com/news/hinge-bio-strengthens-leadership-team-and-publishes-promising-data-for-novel-lupus-treatment-hb2198 2025-09-06T17:11:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hinge-bio-strengthens-leadership-team-and-publishes-promising-data-for-novel-lupus-treatment-hb2198 2025-09-06T17:11:22+00:00 hourly 0.9 https://trial.medpath.com/news/oecd-approves-toxys-toxtracker-for-global-test-guideline-programme-advancing-animal-free-genotoxicity-testing 2025-09-06T17:10:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oecd-approves-toxys-toxtracker-for-global-test-guideline-programme-advancing-animal-free-genotoxicity-testing 2025-09-06T17:10:36+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-reports-positive-phase-3-results-for-palynziq-in-adolescent-pku-patients 2025-09-06T17:10:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarin-reports-positive-phase-3-results-for-palynziq-in-adolescent-pku-patients 2025-09-06T17:10:25+00:00 hourly 0.9 https://trial.medpath.com/news/lila-biologics-partners-with-eli-lilly-for-ai-driven-radioligand-therapy-development 2025-09-06T09:10:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lila-biologics-partners-with-eli-lilly-for-ai-driven-radioligand-therapy-development 2025-09-06T09:10:05+00:00 hourly 0.9 https://trial.medpath.com/news/cognivia-s-covariate-adjustment-method-improves-clinical-trial-precision-by-23-4-for-subjective-endpoints 2025-09-06T05:18:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cognivia-s-covariate-adjustment-method-improves-clinical-trial-precision-by-23-4-for-subjective-endpoints 2025-09-06T05:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-vonvendi-approval-to-include-pediatric-von-willebrand-disease-patients 2025-09-06T05:14:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-vonvendi-approval-to-include-pediatric-von-willebrand-disease-patients 2025-09-06T05:14:17+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-digital-pathology-methods-transform-trop2-biomarker-assessment-in-nsclc 2025-09-06T02:48:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advanced-digital-pathology-methods-transform-trop2-biomarker-assessment-in-nsclc 2025-09-06T02:48:52+00:00 hourly 0.9 https://trial.medpath.com/news/legend-biotech-explores-dual-listing-strategy-to-accelerate-car-t-therapy-expansion 2025-09-06T01:13:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/legend-biotech-explores-dual-listing-strategy-to-accelerate-car-t-therapy-expansion 2025-09-06T01:13:14+00:00 hourly 0.9 https://trial.medpath.com/news/dupilumab-and-remibrutinib-emerge-as-new-treatment-options-for-chronic-spontaneous-urticaria 2025-09-06T01:11:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dupilumab-and-remibrutinib-emerge-as-new-treatment-options-for-chronic-spontaneous-urticaria 2025-09-06T01:11:24+00:00 hourly 0.9 https://trial.medpath.com/news/fda-implements-import-alert-to-combat-unsafe-glp-1-drug-ingredient-imports-amid-obesity-treatment-shortage 2025-09-06T01:10:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-implements-import-alert-to-combat-unsafe-glp-1-drug-ingredient-imports-amid-obesity-treatment-shortage 2025-09-06T01:10:06+00:00 hourly 0.9 https://trial.medpath.com/news/dbv-technologies-launches-150m-atm-program-to-fund-viaskin-peanut-patch-bla-submissions 2025-09-06T01:09:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dbv-technologies-launches-150m-atm-program-to-fund-viaskin-peanut-patch-bla-submissions 2025-09-06T01:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/dbv-technologies-establishes-150-million-at-the-market-program-to-fund-viaskin-peanut-patch-development 2025-09-06T01:09:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dbv-technologies-establishes-150-million-at-the-market-program-to-fund-viaskin-peanut-patch-development 2025-09-06T01:09:22+00:00 hourly 0.9 https://trial.medpath.com/news/augurex-presents-novel-14-3-3eta-biomarker-data-for-axial-spondyloarthritis-diagnosis-at-acr-convergence-2025 2025-09-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/augurex-presents-novel-14-3-3eta-biomarker-data-for-axial-spondyloarthritis-diagnosis-at-acr-convergence-2025 2025-09-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/curapath-and-cayman-chemical-partner-to-expand-global-access-to-peg-free-lipids-for-next-generation-lnp-therapies 2025-09-05T21:18:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curapath-and-cayman-chemical-partner-to-expand-global-access-to-peg-free-lipids-for-next-generation-lnp-therapies 2025-09-05T21:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/bevacizumab-erlotinib-combination-shows-remarkable-72-response-rate-in-rare-hlrcc-associated-kidney-cancer 2025-09-05T21:17:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bevacizumab-erlotinib-combination-shows-remarkable-72-response-rate-in-rare-hlrcc-associated-kidney-cancer 2025-09-05T21:17:39+00:00 hourly 0.9 https://trial.medpath.com/news/md-anderson-and-phoenix-senolytix-forge-strategic-cross-licensing-agreement-to-advance-injectable-safety-switch-technology-for-cell-and-gene-therapies 2025-09-05T21:16:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/md-anderson-and-phoenix-senolytix-forge-strategic-cross-licensing-agreement-to-advance-injectable-safety-switch-technology-for-cell-and-gene-therapies 2025-09-05T21:16:35+00:00 hourly 0.9 https://trial.medpath.com/news/hengrui-licenses-heart-disease-drug-hrs-1893-to-braveheart-bio-for-65m-upfront-potential-1b-total 2025-09-05T21:15:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hengrui-licenses-heart-disease-drug-hrs-1893-to-braveheart-bio-for-65m-upfront-potential-1b-total 2025-09-05T21:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-researchers-develop-novel-enpp1-inhibitor-stf-1623-to-transform-cold-tumors-into-immunologically-active-targets 2025-09-05T21:15:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-researchers-develop-novel-enpp1-inhibitor-stf-1623-to-transform-cold-tumors-into-immunologically-active-targets 2025-09-05T21:15:15+00:00 hourly 0.9 https://trial.medpath.com/news/algernon-health-secures-500k-investment-and-equipment-deal-to-launch-brain-specific-pet-imaging-network 2025-09-05T21:13:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/algernon-health-secures-500k-investment-and-equipment-deal-to-launch-brain-specific-pet-imaging-network 2025-09-05T21:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/gelteq-initiates-preclinical-trial-for-novel-gel-based-antihistamine-targeting-12b-market 2025-09-05T21:13:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gelteq-initiates-preclinical-trial-for-novel-gel-based-antihistamine-targeting-12b-market 2025-09-05T21:13:12+00:00 hourly 0.9 https://trial.medpath.com/news/federal-court-rules-on-patent-damages-timeline-in-mallinckrodt-airgas-nitric-oxide-therapy-dispute 2025-09-05T21:12:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-court-rules-on-patent-damages-timeline-in-mallinckrodt-airgas-nitric-oxide-therapy-dispute 2025-09-05T21:12:12+00:00 hourly 0.9 https://trial.medpath.com/news/florida-cancer-specialists-presents-real-world-evidence-studies-on-blood-cancers-at-soho-2025 2025-09-05T21:12:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/florida-cancer-specialists-presents-real-world-evidence-studies-on-blood-cancers-at-soho-2025 2025-09-05T21:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/curatis-secures-chf-5-million-distribution-deal-with-phoenix-labs-for-pain-management-and-urology-products 2025-09-05T17:21:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curatis-secures-chf-5-million-distribution-deal-with-phoenix-labs-for-pain-management-and-urology-products 2025-09-05T17:21:32+00:00 hourly 0.9 https://trial.medpath.com/news/mercy-bioanalytics-raises-59-million-series-b-to-commercialize-breakthrough-ovarian-cancer-screening-technology 2025-09-05T17:18:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mercy-bioanalytics-raises-59-million-series-b-to-commercialize-breakthrough-ovarian-cancer-screening-technology 2025-09-05T17:18:03+00:00 hourly 0.9 https://trial.medpath.com/news/who-adds-glp-1-diabetes-drugs-to-essential-medicines-list-excludes-weight-loss-indication 2025-09-05T17:16:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-adds-glp-1-diabetes-drugs-to-essential-medicines-list-excludes-weight-loss-indication 2025-09-05T17:16:41+00:00 hourly 0.9 https://trial.medpath.com/news/aptar-pharma-partners-with-dianosic-to-develop-novel-bioresorbable-intranasal-drug-delivery-platform 2025-09-05T17:16:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptar-pharma-partners-with-dianosic-to-develop-novel-bioresorbable-intranasal-drug-delivery-platform 2025-09-05T17:16:17+00:00 hourly 0.9 https://trial.medpath.com/news/miwendo-solutions-secures-eur1-2-million-to-develop-ai-powered-colonoscopy-device-for-real-time-polyp-characterization 2025-09-05T17:16:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/miwendo-solutions-secures-eur1-2-million-to-develop-ai-powered-colonoscopy-device-for-real-time-polyp-characterization 2025-09-05T17:16:01+00:00 hourly 0.9 https://trial.medpath.com/news/uniqure-s-amt-191-gene-therapy-shows-sustained-enzyme-activity-and-ert-discontinuation-in-fabry-disease-phase-i-iia-trial 2025-09-05T17:15:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uniqure-s-amt-191-gene-therapy-shows-sustained-enzyme-activity-and-ert-discontinuation-in-fabry-disease-phase-i-iia-trial 2025-09-05T17:15:11+00:00 hourly 0.9 https://trial.medpath.com/news/ema-safety-committee-initiates-review-of-levamisole-following-fatal-leukoencephalopathy-case 2025-09-05T17:14:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-safety-committee-initiates-review-of-levamisole-following-fatal-leukoencephalopathy-case 2025-09-05T17:14:52+00:00 hourly 0.9 https://trial.medpath.com/news/hutchmed-presents-clinical-data-for-multiple-cancer-therapies-at-major-oncology-conferences 2025-09-05T17:14:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hutchmed-presents-clinical-data-for-multiple-cancer-therapies-at-major-oncology-conferences 2025-09-05T17:14:33+00:00 hourly 0.9 https://trial.medpath.com/news/braveheart-bio-raises-185m-series-a-to-advance-hypertrophic-cardiomyopathy-drug-licensed-from-hengrui 2025-09-05T17:14:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/braveheart-bio-raises-185m-series-a-to-advance-hypertrophic-cardiomyopathy-drug-licensed-from-hengrui 2025-09-05T17:14:22+00:00 hourly 0.9 https://trial.medpath.com/news/huadong-medicine-s-ror1-targeting-adc-hdm2005-shows-promising-phase-i-results-in-relapsed-lymphomas 2025-09-05T17:13:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/huadong-medicine-s-ror1-targeting-adc-hdm2005-shows-promising-phase-i-results-in-relapsed-lymphomas 2025-09-05T17:13:23+00:00 hourly 0.9 https://trial.medpath.com/news/avadel-presents-new-lumryz-data-at-world-sleep-2025-demonstrating-real-world-efficacy-in-narcolepsy-treatment 2025-09-05T17:13:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avadel-presents-new-lumryz-data-at-world-sleep-2025-demonstrating-real-world-efficacy-in-narcolepsy-treatment 2025-09-05T17:13:17+00:00 hourly 0.9 https://trial.medpath.com/news/ronovo-surgical-secures-67m-series-d-led-by-johnson-johnson-advances-carina-robotic-platform-commercialization 2025-09-05T17:13:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ronovo-surgical-secures-67m-series-d-led-by-johnson-johnson-advances-carina-robotic-platform-commercialization 2025-09-05T17:13:04+00:00 hourly 0.9 https://trial.medpath.com/news/case-western-reserve-university-launches-9-9m-clinical-trial-for-touch-sensing-prosthetic-arms 2025-09-05T17:13:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/case-western-reserve-university-launches-9-9m-clinical-trial-for-touch-sensing-prosthetic-arms 2025-09-05T17:13:02+00:00 hourly 0.9 https://trial.medpath.com/news/gel4med-s-g4derm-plus-shows-rapid-healing-in-complex-diabetic-foot-ulcers-with-novel-biomimetic-matrix-technology 2025-09-05T17:11:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gel4med-s-g4derm-plus-shows-rapid-healing-in-complex-diabetic-foot-ulcers-with-novel-biomimetic-matrix-technology 2025-09-05T17:11:55+00:00 hourly 0.9 https://trial.medpath.com/news/idorsia-launches-impact-htn-initiative-with-stanford-and-duke-to-transform-difficult-to-control-hypertension-care 2025-09-05T17:10:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/idorsia-launches-impact-htn-initiative-with-stanford-and-duke-to-transform-difficult-to-control-hypertension-care 2025-09-05T17:10:40+00:00 hourly 0.9 https://trial.medpath.com/news/ai-platform-connects-nearly-300-duchenne-patients-to-clinical-trials-and-expanded-access-programs 2025-09-05T17:10:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-platform-connects-nearly-300-duchenne-patients-to-clinical-trials-and-expanded-access-programs 2025-09-05T17:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/university-hospitals-receives-3-5m-gift-to-triple-cancer-clinical-trials-capacity-by-2030 2025-09-05T16:22:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-hospitals-receives-3-5m-gift-to-triple-cancer-clinical-trials-capacity-by-2030 2025-09-05T16:22:39+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-lifesciences-secures-two-strategic-partnerships-for-novel-505-b-2-oncology-products-in-us-market 2025-09-05T13:23:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zydus-lifesciences-secures-two-strategic-partnerships-for-novel-505-b-2-oncology-products-in-us-market 2025-09-05T13:23:12+00:00 hourly 0.9 https://trial.medpath.com/news/scynexis-presents-promising-data-on-scy-247-against-drug-resistant-fungal-infections-at-timm-12-congress 2025-09-05T13:19:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scynexis-presents-promising-data-on-scy-247-against-drug-resistant-fungal-infections-at-timm-12-congress 2025-09-05T13:19:27+00:00 hourly 0.9 https://trial.medpath.com/news/myriad-s-precise-mrd-test-shows-promise-in-detecting-circulating-tumor-dna-in-oligometastatic-renal-cell-carcinoma 2025-09-05T13:16:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myriad-s-precise-mrd-test-shows-promise-in-detecting-circulating-tumor-dna-in-oligometastatic-renal-cell-carcinoma 2025-09-05T13:16:59+00:00 hourly 0.9 https://trial.medpath.com/news/biosecure-act-returns-to-congressional-agenda-with-revised-amendment-targeting-chinese-biotechnology-companies 2025-09-05T13:14:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biosecure-act-returns-to-congressional-agenda-with-revised-amendment-targeting-chinese-biotechnology-companies 2025-09-05T13:14:30+00:00 hourly 0.9 https://trial.medpath.com/news/sophia-genetics-partners-with-belgium-s-jessa-ziekenhuis-to-advance-precision-oncology-through-ai-driven-genomic-platform 2025-09-05T13:14:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sophia-genetics-partners-with-belgium-s-jessa-ziekenhuis-to-advance-precision-oncology-through-ai-driven-genomic-platform 2025-09-05T13:14:27+00:00 hourly 0.9 https://trial.medpath.com/news/catalyst-oncology-enables-accelerated-fda-approval-for-first-in-class-ovarian-cancer-therapy 2025-09-05T13:13:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/catalyst-oncology-enables-accelerated-fda-approval-for-first-in-class-ovarian-cancer-therapy 2025-09-05T13:13:54+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-initiates-global-phase-3-trial-for-subcutaneous-pd-l1-inhibitor-envafolimab-in-stage-iii-lung-cancer 2025-09-05T13:12:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-initiates-global-phase-3-trial-for-subcutaneous-pd-l1-inhibitor-envafolimab-in-stage-iii-lung-cancer 2025-09-05T13:12:20+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-data-shows-bispecific-antibodies-deliver-clinical-trial-level-efficacy-in-broader-multiple-myeloma-patient-populations 2025-09-05T10:48:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-data-shows-bispecific-antibodies-deliver-clinical-trial-level-efficacy-in-broader-multiple-myeloma-patient-populations 2025-09-05T10:48:18+00:00 hourly 0.9 https://trial.medpath.com/news/hopehealth-launches-first-clinical-trial-site-for-bristol-myers-squibb-s-lupus-drug-deucravacitinib 2025-09-05T09:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hopehealth-launches-first-clinical-trial-site-for-bristol-myers-squibb-s-lupus-drug-deucravacitinib 2025-09-05T09:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-project-optimus-drives-27-surge-in-bayesian-trial-designs-transforming-early-phase-cancer-drug-development 2025-09-05T09:10:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-project-optimus-drives-27-surge-in-bayesian-trial-designs-transforming-early-phase-cancer-drug-development 2025-09-05T09:10:02+00:00 hourly 0.9 https://trial.medpath.com/news/indaptus-therapeutics-reports-partial-response-with-decoy20-in-urothelial-cancer-patient 2025-09-05T06:44:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indaptus-therapeutics-reports-partial-response-with-decoy20-in-urothelial-cancer-patient 2025-09-05T06:44:52+00:00 hourly 0.9 https://trial.medpath.com/news/tenon-medical-s-catamaran-si-joint-fusion-system-shows-83-fusion-rate-and-significant-pain-reduction-at-12-months 2025-09-05T06:44:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tenon-medical-s-catamaran-si-joint-fusion-system-shows-83-fusion-rate-and-significant-pain-reduction-at-12-months 2025-09-05T06:44:46+00:00 hourly 0.9 https://trial.medpath.com/news/silexion-therapeutics-partners-with-ams-for-phase-2-3-trials-of-kras-targeting-sirna-therapy-sil204 2025-09-05T06:44:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/silexion-therapeutics-partners-with-ams-for-phase-2-3-trials-of-kras-targeting-sirna-therapy-sil204 2025-09-05T06:44:33+00:00 hourly 0.9 https://trial.medpath.com/news/rybrevant-plus-lazcluze-demonstrates-superior-survival-in-first-line-egfr-mutated-nsclc 2025-09-05T06:43:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rybrevant-plus-lazcluze-demonstrates-superior-survival-in-first-line-egfr-mutated-nsclc 2025-09-05T06:43:56+00:00 hourly 0.9 https://trial.medpath.com/news/predictive-biomarkers-guide-ruxolitinib-treatment-optimization-in-myelofibrosis-after-15-years-of-clinical-use 2025-09-05T03:12:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/predictive-biomarkers-guide-ruxolitinib-treatment-optimization-in-myelofibrosis-after-15-years-of-clinical-use 2025-09-05T03:12:37+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-nutrition-expert-outlines-dietary-strategies-to-combat-treatment-side-effects-and-support-long-term-survivorship 2025-09-05T03:12:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-nutrition-expert-outlines-dietary-strategies-to-combat-treatment-side-effects-and-support-long-term-survivorship 2025-09-05T03:12:18+00:00 hourly 0.9 https://trial.medpath.com/news/novel-gcgr-glp-1r-dual-agonist-tb001-shows-promise-for-treating-kidney-fibrosis 2025-09-05T03:04:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-gcgr-glp-1r-dual-agonist-tb001-shows-promise-for-treating-kidney-fibrosis 2025-09-05T03:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/glycolytic-reprogramming-emerges-as-key-therapeutic-target-in-gastric-cancer 2025-09-05T02:37:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glycolytic-reprogramming-emerges-as-key-therapeutic-target-in-gastric-cancer 2025-09-05T02:37:11+00:00 hourly 0.9 https://trial.medpath.com/news/evernorth-health-services-makes-3-5-billion-investment-in-shields-health-solutions-to-expand-specialty-pharmacy-network 2025-09-05T01:02:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evernorth-health-services-makes-3-5-billion-investment-in-shields-health-solutions-to-expand-specialty-pharmacy-network 2025-09-05T01:02:49+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-launches-to-evaluate-dietary-supplements-for-cognitive-function-and-energy 2025-09-05T01:02:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-launches-to-evaluate-dietary-supplements-for-cognitive-function-and-energy 2025-09-05T01:02:11+00:00 hourly 0.9 https://trial.medpath.com/news/lpoxy-therapeutics-secures-28m-series-a-to-launch-pivotal-trial-for-novel-c-difficile-prevention-therapy 2025-09-05T01:00:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lpoxy-therapeutics-secures-28m-series-a-to-launch-pivotal-trial-for-novel-c-difficile-prevention-therapy 2025-09-05T01:00:01+00:00 hourly 0.9 https://trial.medpath.com/news/purple-biotech-raises-6-million-in-public-offering-to-advance-novel-cancer-immunotherapy-pipeline 2025-09-05T00:59:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/purple-biotech-raises-6-million-in-public-offering-to-advance-novel-cancer-immunotherapy-pipeline 2025-09-05T00:59:36+00:00 hourly 0.9 https://trial.medpath.com/news/atlas-venture-raises-400m-opportunity-fund-to-support-biotech-portfolio-companies 2025-09-05T00:58:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atlas-venture-raises-400m-opportunity-fund-to-support-biotech-portfolio-companies 2025-09-05T00:58:28+00:00 hourly 0.9 https://trial.medpath.com/news/octave-bioscience-secures-35-6m-series-c-funding-to-advance-multiple-sclerosis-precision-testing-platform 2025-09-05T00:58:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/octave-bioscience-secures-35-6m-series-c-funding-to-advance-multiple-sclerosis-precision-testing-platform 2025-09-05T00:58:01+00:00 hourly 0.9 https://trial.medpath.com/news/baylor-college-of-medicine-partners-with-site-tx-to-advance-immune-targeted-small-molecule-drug-discovery 2025-09-05T00:56:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/baylor-college-of-medicine-partners-with-site-tx-to-advance-immune-targeted-small-molecule-drug-discovery 2025-09-05T00:56:39+00:00 hourly 0.9 https://trial.medpath.com/news/4dmedical-receives-fda-clearance-for-revolutionary-ct-vq-lung-imaging-software 2025-09-05T00:55:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4dmedical-receives-fda-clearance-for-revolutionary-ct-vq-lung-imaging-software 2025-09-05T00:55:38+00:00 hourly 0.9 https://trial.medpath.com/news/cls-receives-fda-clearance-to-expand-clearpoint-prism-neuro-laser-therapy-system-to-1-5t-mri-doubling-u-s-market-access 2025-09-05T00:55:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cls-receives-fda-clearance-to-expand-clearpoint-prism-neuro-laser-therapy-system-to-1-5t-mri-doubling-u-s-market-access 2025-09-05T00:55:29+00:00 hourly 0.9 https://trial.medpath.com/news/phage-therapy-advances-in-environmental-applications-show-promise-for-antimicrobial-resistance-control 2025-09-05T00:47:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phage-therapy-advances-in-environmental-applications-show-promise-for-antimicrobial-resistance-control 2025-09-05T00:47:48+00:00 hourly 0.9 https://trial.medpath.com/news/inhaled-il-15-immunotherapy-shows-promise-in-veterinary-cancer-trial-with-delayed-response-pattern 2025-09-05T00:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inhaled-il-15-immunotherapy-shows-promise-in-veterinary-cancer-trial-with-delayed-response-pattern 2025-09-05T00:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/boomerang-medical-secures-20m-series-b-to-advance-first-pivotal-neuromodulation-trial-for-ulcerative-colitis 2025-09-04T23:05:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boomerang-medical-secures-20m-series-b-to-advance-first-pivotal-neuromodulation-trial-for-ulcerative-colitis 2025-09-04T23:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-expands-manufacturing-footprint-in-north-carolina-despite-global-workforce-reduction 2025-09-04T23:05:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-expands-manufacturing-footprint-in-north-carolina-despite-global-workforce-reduction 2025-09-04T23:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-s-hugo-robotic-surgery-system-achieves-100-success-rate-in-first-u-s-hernia-repair-study 2025-09-04T23:03:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-s-hugo-robotic-surgery-system-achieves-100-success-rate-in-first-u-s-hernia-repair-study 2025-09-04T23:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/predictive-oncology-partners-with-every-cure-to-accelerate-ai-driven-drug-repurposing-for-cancer-treatment 2025-09-04T20:45:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/predictive-oncology-partners-with-every-cure-to-accelerate-ai-driven-drug-repurposing-for-cancer-treatment 2025-09-04T20:45:33+00:00 hourly 0.9 https://trial.medpath.com/news/ketryx-secures-39m-series-b-to-accelerate-ai-powered-compliance-platform-for-life-sciences 2025-09-04T20:44:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ketryx-secures-39m-series-b-to-accelerate-ai-powered-compliance-platform-for-life-sciences 2025-09-04T20:44:56+00:00 hourly 0.9 https://trial.medpath.com/news/sugar-coated-nanoparticles-show-promise-for-triple-negative-breast-cancer-treatment 2025-09-04T20:44:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sugar-coated-nanoparticles-show-promise-for-triple-negative-breast-cancer-treatment 2025-09-04T20:44:36+00:00 hourly 0.9 https://trial.medpath.com/news/black-diamond-therapeutics-completes-enrollment-in-phase-ii-study-of-egfr-inhibitor-silevertinib-for-nsclc 2025-09-04T20:44:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/black-diamond-therapeutics-completes-enrollment-in-phase-ii-study-of-egfr-inhibitor-silevertinib-for-nsclc 2025-09-04T20:44:20+00:00 hourly 0.9 https://trial.medpath.com/news/methotrexate-shows-cardiovascular-benefits-beyond-arthritis-treatment-in-new-study 2025-09-04T20:43:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/methotrexate-shows-cardiovascular-benefits-beyond-arthritis-treatment-in-new-study 2025-09-04T20:43:51+00:00 hourly 0.9 https://trial.medpath.com/news/rapafusyn-pharmaceuticals-secures-44-million-series-a-to-advance-non-degrading-molecular-glue-platform 2025-09-04T20:43:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rapafusyn-pharmaceuticals-secures-44-million-series-a-to-advance-non-degrading-molecular-glue-platform 2025-09-04T20:43:49+00:00 hourly 0.9 https://trial.medpath.com/news/bluejay-therapeutics-initiates-phase-3-azure-2-trial-comparing-brelovitug-to-hepcludex-for-chronic-hepatitis-d 2025-09-04T17:24:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bluejay-therapeutics-initiates-phase-3-azure-2-trial-comparing-brelovitug-to-hepcludex-for-chronic-hepatitis-d 2025-09-04T17:24:23+00:00 hourly 0.9 https://trial.medpath.com/news/senseonics-to-take-over-eversense-365-cgm-commercialization-from-ascensia-in-strategic-transition 2025-09-04T17:20:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senseonics-to-take-over-eversense-365-cgm-commercialization-from-ascensia-in-strategic-transition 2025-09-04T17:20:07+00:00 hourly 0.9 https://trial.medpath.com/news/illumina-launches-protein-prep-assay-to-accelerate-drug-discovery-through-large-scale-proteomics 2025-09-04T17:19:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/illumina-launches-protein-prep-assay-to-accelerate-drug-discovery-through-large-scale-proteomics 2025-09-04T17:19:56+00:00 hourly 0.9 https://trial.medpath.com/news/atelerix-partners-with-rodon-global-to-revolutionize-biomedical-cold-chain-logistics-with-cryo-free-technology 2025-09-04T17:17:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atelerix-partners-with-rodon-global-to-revolutionize-biomedical-cold-chain-logistics-with-cryo-free-technology 2025-09-04T17:17:35+00:00 hourly 0.9 https://trial.medpath.com/news/vyome-s-vt-1953-demonstrates-significant-efficacy-in-phase-2-trial-for-malignant-fungating-wounds 2025-09-04T17:17:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vyome-s-vt-1953-demonstrates-significant-efficacy-in-phase-2-trial-for-malignant-fungating-wounds 2025-09-04T17:17:32+00:00 hourly 0.9 https://trial.medpath.com/news/kadimastem-secures-hong-kong-patent-for-isletrx-stem-cell-diabetes-therapy 2025-09-04T17:17:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kadimastem-secures-hong-kong-patent-for-isletrx-stem-cell-diabetes-therapy 2025-09-04T17:17:06+00:00 hourly 0.9 https://trial.medpath.com/news/euda-secures-distribution-rights-for-t-cell-immunotherapy-in-malaysia-at-8000-per-treatment 2025-09-04T17:16:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/euda-secures-distribution-rights-for-t-cell-immunotherapy-in-malaysia-at-8000-per-treatment 2025-09-04T17:16:34+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-ind-application-for-biib142-first-irak4-degrader-to-enter-clinical-development-for-autoimmune-diseases 2025-09-04T17:15:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-ind-application-for-biib142-first-irak4-degrader-to-enter-clinical-development-for-autoimmune-diseases 2025-09-04T17:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/a-race-against-blindness-awards-1-million-to-advance-axv-101-gene-therapy-for-childhood-blindness 2025-09-04T17:15:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-race-against-blindness-awards-1-million-to-advance-axv-101-gene-therapy-for-childhood-blindness 2025-09-04T17:15:46+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-presents-phase-ib-data-on-novel-orexin-agonist-e2086-for-narcolepsy-at-world-sleep-2025 2025-09-04T17:14:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eisai-presents-phase-ib-data-on-novel-orexin-agonist-e2086-for-narcolepsy-at-world-sleep-2025 2025-09-04T17:14:30+00:00 hourly 0.9 https://trial.medpath.com/news/atara-biotherapeutics-appoints-new-board-chair-as-company-streamlines-operations-ahead-of-fda-decision 2025-09-04T17:13:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atara-biotherapeutics-appoints-new-board-chair-as-company-streamlines-operations-ahead-of-fda-decision 2025-09-04T17:13:43+00:00 hourly 0.9 https://trial.medpath.com/news/theracryf-advances-orexin-1-receptor-antagonist-for-addiction-treatment-with-korean-patent-grant-and-manufacturing-milestones 2025-09-04T17:13:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theracryf-advances-orexin-1-receptor-antagonist-for-addiction-treatment-with-korean-patent-grant-and-manufacturing-milestones 2025-09-04T17:13:09+00:00 hourly 0.9 https://trial.medpath.com/news/enveda-biosciences-raises-150m-series-d-to-advance-ai-driven-drug-discovery-platform 2025-09-04T17:12:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enveda-biosciences-raises-150m-series-d-to-advance-ai-driven-drug-discovery-platform 2025-09-04T17:12:38+00:00 hourly 0.9 https://trial.medpath.com/news/orbital-therapeutics-appoints-adam-raff-as-senior-vp-to-advance-rna-medicine-platform-toward-clinical-trials 2025-09-04T17:12:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orbital-therapeutics-appoints-adam-raff-as-senior-vp-to-advance-rna-medicine-platform-toward-clinical-trials 2025-09-04T17:12:33+00:00 hourly 0.9 https://trial.medpath.com/news/syantra-launches-immuno-oncology-therapeutic-division-to-reverse-cancer-related-immune-cell-corruption 2025-09-04T17:12:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syantra-launches-immuno-oncology-therapeutic-division-to-reverse-cancer-related-immune-cell-corruption 2025-09-04T17:12:10+00:00 hourly 0.9 https://trial.medpath.com/news/revalia-bio-secures-14-5m-to-revolutionize-drug-development-with-human-organ-testing-platform 2025-09-04T17:12:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revalia-bio-secures-14-5m-to-revolutionize-drug-development-with-human-organ-testing-platform 2025-09-04T17:12:07+00:00 hourly 0.9 https://trial.medpath.com/news/neurosense-therapeutics-secures-500000-bridge-financing-at-40-premium-ahead-of-key-als-drug-milestones 2025-09-04T17:11:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurosense-therapeutics-secures-500000-bridge-financing-at-40-premium-ahead-of-key-als-drug-milestones 2025-09-04T17:11:56+00:00 hourly 0.9 https://trial.medpath.com/news/neuphoria-therapeutics-completes-phase-3-enrollment-for-bnc-210-social-anxiety-disorder-treatment 2025-09-04T17:11:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuphoria-therapeutics-completes-phase-3-enrollment-for-bnc-210-social-anxiety-disorder-treatment 2025-09-04T17:11:21+00:00 hourly 0.9 https://trial.medpath.com/news/accro-bioscience-to-present-positive-phase-ii-results-for-ac-201-tyk2-jak1-inhibitor-in-plaque-psoriasis-at-eadv-congress 2025-09-04T17:11:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accro-bioscience-to-present-positive-phase-ii-results-for-ac-201-tyk2-jak1-inhibitor-in-plaque-psoriasis-at-eadv-congress 2025-09-04T17:11:19+00:00 hourly 0.9 https://trial.medpath.com/news/lambdavision-secures-7m-seed-funding-to-advance-space-manufactured-artificial-retina-for-blindness-treatment 2025-09-04T17:10:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lambdavision-secures-7m-seed-funding-to-advance-space-manufactured-artificial-retina-for-blindness-treatment 2025-09-04T17:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/al-s-pharma-reports-positive-phase-2-results-for-ap-101-in-als-treatment 2025-09-04T17:10:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/al-s-pharma-reports-positive-phase-2-results-for-ap-101-in-als-treatment 2025-09-04T17:10:54+00:00 hourly 0.9 https://trial.medpath.com/news/science-37-and-catalent-partner-to-transform-clinical-trial-access-through-direct-to-patient-drug-delivery 2025-09-04T17:10:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/science-37-and-catalent-partner-to-transform-clinical-trial-access-through-direct-to-patient-drug-delivery 2025-09-04T17:10:06+00:00 hourly 0.9 https://trial.medpath.com/news/onco3r-therapeutics-receives-regulatory-approval-for-first-in-human-trial-of-novel-sik3-inhibitor-o3r-5671 2025-09-04T17:09:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onco3r-therapeutics-receives-regulatory-approval-for-first-in-human-trial-of-novel-sik3-inhibitor-o3r-5671 2025-09-04T17:09:46+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-and-synthon-partner-to-launch-generic-multiple-sclerosis-drug-in-637-million-us-market 2025-09-04T17:09:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zydus-and-synthon-partner-to-launch-generic-multiple-sclerosis-drug-in-637-million-us-market 2025-09-04T17:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/new-real-time-imaging-method-advances-therapeutic-antibody-immunogenicity-risk-assessment 2025-09-04T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-real-time-imaging-method-advances-therapeutic-antibody-immunogenicity-risk-assessment 2025-09-04T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/johns-hopkins-develops-urine-based-biomarker-panel-for-prostate-cancer-detection-with-91-accuracy 2025-09-04T13:21:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johns-hopkins-develops-urine-based-biomarker-panel-for-prostate-cancer-detection-with-91-accuracy 2025-09-04T13:21:18+00:00 hourly 0.9 https://trial.medpath.com/news/northwestern-university-develops-novel-nanostructure-to-triple-crispr-gene-editing-efficiency 2025-09-04T13:18:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northwestern-university-develops-novel-nanostructure-to-triple-crispr-gene-editing-efficiency 2025-09-04T13:18:11+00:00 hourly 0.9 https://trial.medpath.com/news/arecor-receives-fda-approval-for-phase-2-trial-of-ultra-concentrated-insulin-at278-in-automated-delivery-systems 2025-09-04T13:14:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arecor-receives-fda-approval-for-phase-2-trial-of-ultra-concentrated-insulin-at278-in-automated-delivery-systems 2025-09-04T13:14:39+00:00 hourly 0.9 https://trial.medpath.com/news/aspen-pharmacare-to-launch-generic-weight-loss-drugs-at-half-the-price-of-ozempic-and-wegovy 2025-09-04T13:13:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspen-pharmacare-to-launch-generic-weight-loss-drugs-at-half-the-price-of-ozempic-and-wegovy 2025-09-04T13:13:43+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-shares-plummet-10-as-amlitelimab-phase-iii-data-falls-short-of-dupixent-expectations 2025-09-04T13:12:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-shares-plummet-10-as-amlitelimab-phase-iii-data-falls-short-of-dupixent-expectations 2025-09-04T13:12:52+00:00 hourly 0.9 https://trial.medpath.com/news/mrm-health-secures-eur55-million-series-b-to-advance-microbiome-based-therapeutics-for-inflammatory-diseases 2025-09-04T13:12:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrm-health-secures-eur55-million-series-b-to-advance-microbiome-based-therapeutics-for-inflammatory-diseases 2025-09-04T13:12:40+00:00 hourly 0.9 https://trial.medpath.com/news/multiomic-health-partners-with-serbia-s-bio4-campus-to-develop-ai-driven-precision-medicine-for-cardio-renal-metabolic-diseases 2025-09-04T13:12:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multiomic-health-partners-with-serbia-s-bio4-campus-to-develop-ai-driven-precision-medicine-for-cardio-renal-metabolic-diseases 2025-09-04T13:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/shield-therapeutics-accrufer-receives-fda-priority-review-for-pediatric-iron-deficiency-anemia 2025-09-04T13:11:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shield-therapeutics-accrufer-receives-fda-priority-review-for-pediatric-iron-deficiency-anemia 2025-09-04T13:11:33+00:00 hourly 0.9 https://trial.medpath.com/news/walden-biosciences-engages-former-fda-director-to-advance-wal0921-phase-2-trial-in-rare-kidney-diseases 2025-09-04T13:10:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/walden-biosciences-engages-former-fda-director-to-advance-wal0921-phase-2-trial-in-rare-kidney-diseases 2025-09-04T13:10:41+00:00 hourly 0.9 https://trial.medpath.com/news/sentec-receives-fda-clearance-for-first-eit-system-approved-for-premature-infants-in-the-united-states 2025-09-04T13:10:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sentec-receives-fda-clearance-for-first-eit-system-approved-for-premature-infants-in-the-united-states 2025-09-04T13:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/semaglutide-shows-promise-in-reducing-cocaine-addiction-in-preclinical-study 2025-09-04T09:11:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/semaglutide-shows-promise-in-reducing-cocaine-addiction-in-preclinical-study 2025-09-04T09:11:40+00:00 hourly 0.9 https://trial.medpath.com/news/perspective-therapeutics-names-joel-sendek-as-cfo-to-advance-alpha-radiopharmaceutical-programs 2025-09-04T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/perspective-therapeutics-names-joel-sendek-as-cfo-to-advance-alpha-radiopharmaceutical-programs 2025-09-04T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/west-coast-states-form-health-alliance-to-counter-federal-cdc-changes-and-maintain-science-based-vaccine-guidance 2025-09-04T06:50:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/west-coast-states-form-health-alliance-to-counter-federal-cdc-changes-and-maintain-science-based-vaccine-guidance 2025-09-04T06:50:54+00:00 hourly 0.9 https://trial.medpath.com/news/multiple-myeloma-survival-nearly-doubles-over-15-years-despite-remaining-incurable 2025-09-04T02:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multiple-myeloma-survival-nearly-doubles-over-15-years-despite-remaining-incurable 2025-09-04T02:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/reveal-healthtech-secures-7-2m-series-a-to-advance-ai-driven-healthcare-solutions 2025-09-04T01:23:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reveal-healthtech-secures-7-2m-series-a-to-advance-ai-driven-healthcare-solutions 2025-09-04T01:23:28+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-sciences-breaks-ground-on-32-billion-ai-enabled-biologics-development-center 2025-09-04T01:21:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-sciences-breaks-ground-on-32-billion-ai-enabled-biologics-development-center 2025-09-04T01:21:28+00:00 hourly 0.9 https://trial.medpath.com/news/radiance-biopharma-secures-exclusive-license-for-first-in-class-bispecific-adc-targeting-c-met-and-egfr 2025-09-04T01:17:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiance-biopharma-secures-exclusive-license-for-first-in-class-bispecific-adc-targeting-c-met-and-egfr 2025-09-04T01:17:56+00:00 hourly 0.9 https://trial.medpath.com/news/mytos-launches-automated-cdmo-to-scale-stem-cell-therapy-manufacturing 2025-09-04T01:17:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mytos-launches-automated-cdmo-to-scale-stem-cell-therapy-manufacturing 2025-09-04T01:17:04+00:00 hourly 0.9 https://trial.medpath.com/news/avadel-pharmaceuticals-acquires-exclusive-global-rights-to-valiloxybate-for-sleep-disorders 2025-09-04T01:16:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avadel-pharmaceuticals-acquires-exclusive-global-rights-to-valiloxybate-for-sleep-disorders 2025-09-04T01:16:15+00:00 hourly 0.9 https://trial.medpath.com/news/single-dose-benzathine-penicillin-g-proves-as-effective-as-three-dose-regimen-for-early-syphilis-treatment 2025-09-04T01:14:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-dose-benzathine-penicillin-g-proves-as-effective-as-three-dose-regimen-for-early-syphilis-treatment 2025-09-04T01:14:30+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-prepares-for-potential-first-in-class-spinocerebellar-ataxia-drug-launch-as-fda-decision-looms 2025-09-04T01:13:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biohaven-prepares-for-potential-first-in-class-spinocerebellar-ataxia-drug-launch-as-fda-decision-looms 2025-09-04T01:13:43+00:00 hourly 0.9 https://trial.medpath.com/news/vaxiion-therapeutics-advances-vax014-bacterial-minicell-therapy-to-phase-1b-combination-study 2025-09-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaxiion-therapeutics-advances-vax014-bacterial-minicell-therapy-to-phase-1b-combination-study 2025-09-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ge-healthcare-receives-fda-clearance-for-revolution-vibe-ct-system-targeting-complex-cardiac-imaging 2025-09-03T21:16:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ge-healthcare-receives-fda-clearance-for-revolution-vibe-ct-system-targeting-complex-cardiac-imaging 2025-09-03T21:16:42+00:00 hourly 0.9 https://trial.medpath.com/news/immunovant-s-batoclimab-shows-sustained-remission-in-graves-disease-patients-six-months-after-treatment 2025-09-03T21:16:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunovant-s-batoclimab-shows-sustained-remission-in-graves-disease-patients-six-months-after-treatment 2025-09-03T21:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/gifthealth-acquires-occam-health-services-to-create-digital-pharmacy-platform-for-enhanced-patient-access 2025-09-03T21:15:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gifthealth-acquires-occam-health-services-to-create-digital-pharmacy-platform-for-enhanced-patient-access 2025-09-03T21:15:42+00:00 hourly 0.9 https://trial.medpath.com/news/artelo-biosciences-reports-promising-phase-2-results-for-art27-13-in-cancer-cachexia-treatment 2025-09-03T21:15:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artelo-biosciences-reports-promising-phase-2-results-for-art27-13-in-cancer-cachexia-treatment 2025-09-03T21:15:39+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-utah-researchers-discover-papb-enzyme-for-enhanced-peptide-drug-development 2025-09-03T21:15:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-utah-researchers-discover-papb-enzyme-for-enhanced-peptide-drug-development 2025-09-03T21:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/bluewhale-bio-doses-first-patient-with-novel-cell-derived-nanoparticle-technology-for-car-t-manufacturing 2025-09-03T21:15:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bluewhale-bio-doses-first-patient-with-novel-cell-derived-nanoparticle-technology-for-car-t-manufacturing 2025-09-03T21:15:18+00:00 hourly 0.9 https://trial.medpath.com/news/gd2-directed-car-t-cell-therapy-shows-promise-in-pediatric-brain-cancer-with-complete-response-in-one-patient 2025-09-03T21:14:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gd2-directed-car-t-cell-therapy-shows-promise-in-pediatric-brain-cancer-with-complete-response-in-one-patient 2025-09-03T21:14:51+00:00 hourly 0.9 https://trial.medpath.com/news/wave-life-sciences-wve-006-demonstrates-durable-aat-protein-production-in-alpha-1-antitrypsin-deficiency-trial 2025-09-03T21:14:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wave-life-sciences-wve-006-demonstrates-durable-aat-protein-production-in-alpha-1-antitrypsin-deficiency-trial 2025-09-03T21:14:30+00:00 hourly 0.9 https://trial.medpath.com/news/merck-kgaa-appoints-david-weinreich-as-global-head-of-r-d-to-revitalize-healthcare-pipeline 2025-09-03T21:13:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-kgaa-appoints-david-weinreich-as-global-head-of-r-d-to-revitalize-healthcare-pipeline 2025-09-03T21:13:20+00:00 hourly 0.9 https://trial.medpath.com/news/acute-liver-failure-pipeline-shows-promise-with-5-therapies-in-development-despite-recent-setbacks 2025-09-03T21:12:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acute-liver-failure-pipeline-shows-promise-with-5-therapies-in-development-despite-recent-setbacks 2025-09-03T21:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/corstasis-therapeutics-secures-patent-for-subcutaneous-bumetanide-formulations-ahead-of-enbumyst-pdufa-date 2025-09-03T21:11:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corstasis-therapeutics-secures-patent-for-subcutaneous-bumetanide-formulations-ahead-of-enbumyst-pdufa-date 2025-09-03T21:11:57+00:00 hourly 0.9 https://trial.medpath.com/news/ctc-guided-egfr-inhibitor-therapy-achieves-14-month-response-in-metastatic-hepatocellular-carcinoma 2025-09-03T21:11:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ctc-guided-egfr-inhibitor-therapy-achieves-14-month-response-in-metastatic-hepatocellular-carcinoma 2025-09-03T21:11:40+00:00 hourly 0.9 https://trial.medpath.com/news/pharmala-establishes-australian-subsidiary-to-advance-mdma-clinical-research-and-development 2025-09-03T21:10:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmala-establishes-australian-subsidiary-to-advance-mdma-clinical-research-and-development 2025-09-03T21:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/wave-life-sciences-rna-editing-therapy-shows-therapeutic-promise-in-alpha-1-antitrypsin-deficiency-despite-mixed-investor-reception 2025-09-03T21:09:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wave-life-sciences-rna-editing-therapy-shows-therapeutic-promise-in-alpha-1-antitrypsin-deficiency-despite-mixed-investor-reception 2025-09-03T21:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/modified-car-inkt-therapy-achieves-complete-remission-in-high-risk-childhood-leukemia-mouse-models 2025-09-03T17:22:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/modified-car-inkt-therapy-achieves-complete-remission-in-high-risk-childhood-leukemia-mouse-models 2025-09-03T17:22:05+00:00 hourly 0.9 https://trial.medpath.com/news/upc-court-of-appeal-grants-first-pharmaceutical-preliminary-injunction-setting-new-standard-for-generic-drug-market-entry 2025-09-03T17:21:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/upc-court-of-appeal-grants-first-pharmaceutical-preliminary-injunction-setting-new-standard-for-generic-drug-market-entry 2025-09-03T17:21:12+00:00 hourly 0.9 https://trial.medpath.com/news/charles-river-laboratories-integrates-akadeum-s-microbubble-technology-into-cell-therapy-manufacturing-platform 2025-09-03T17:21:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/charles-river-laboratories-integrates-akadeum-s-microbubble-technology-into-cell-therapy-manufacturing-platform 2025-09-03T17:21:01+00:00 hourly 0.9 https://trial.medpath.com/news/ogrd-alliance-announces-plpc-db-non-cellular-oncology-immunotherapy-platform-for-global-acquisition 2025-09-03T17:20:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ogrd-alliance-announces-plpc-db-non-cellular-oncology-immunotherapy-platform-for-global-acquisition 2025-09-03T17:20:58+00:00 hourly 0.9 https://trial.medpath.com/news/de-escalated-radiation-therapy-reduces-toxicity-while-maintaining-cure-rates-in-hpv-positive-oropharyngeal-cancer 2025-09-03T17:20:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/de-escalated-radiation-therapy-reduces-toxicity-while-maintaining-cure-rates-in-hpv-positive-oropharyngeal-cancer 2025-09-03T17:20:03+00:00 hourly 0.9 https://trial.medpath.com/news/kura-oncology-showcases-preclinical-data-for-next-generation-fti-ko-2806-in-combination-therapies 2025-09-03T17:19:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kura-oncology-showcases-preclinical-data-for-next-generation-fti-ko-2806-in-combination-therapies 2025-09-03T17:19:27+00:00 hourly 0.9 https://trial.medpath.com/news/parabilis-medicines-appoints-fawzi-benzaghou-as-chief-medical-officer-to-advance-undruggable-cancer-targets 2025-09-03T17:18:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parabilis-medicines-appoints-fawzi-benzaghou-as-chief-medical-officer-to-advance-undruggable-cancer-targets 2025-09-03T17:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/xortx-therapeutics-initiates-ind-preparation-for-xorlotm-gout-treatment-following-fda-guidance 2025-09-03T17:18:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xortx-therapeutics-initiates-ind-preparation-for-xorlotm-gout-treatment-following-fda-guidance 2025-09-03T17:18:38+00:00 hourly 0.9 https://trial.medpath.com/news/precigen-secures-125-million-credit-facility-to-advance-papzimeos-commercialization 2025-09-03T17:17:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precigen-secures-125-million-credit-facility-to-advance-papzimeos-commercialization 2025-09-03T17:17:24+00:00 hourly 0.9 https://trial.medpath.com/news/andelyn-biosciences-partners-with-tern-therapeutics-for-late-stage-manufacturing-of-cln2-batten-disease-gene-therapy 2025-09-03T17:17:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/andelyn-biosciences-partners-with-tern-therapeutics-for-late-stage-manufacturing-of-cln2-batten-disease-gene-therapy 2025-09-03T17:17:10+00:00 hourly 0.9 https://trial.medpath.com/news/ori-biotech-s-iro-platform-becomes-one-of-first-technologies-to-receive-fda-advanced-manufacturing-technology-designation 2025-09-03T17:17:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ori-biotech-s-iro-platform-becomes-one-of-first-technologies-to-receive-fda-advanced-manufacturing-technology-designation 2025-09-03T17:17:08+00:00 hourly 0.9 https://trial.medpath.com/news/strategic-partnerships-transform-gene-therapy-manufacturing-for-rare-diseases-as-market-reaches-11-4-billion 2025-09-03T17:16:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strategic-partnerships-transform-gene-therapy-manufacturing-for-rare-diseases-as-market-reaches-11-4-billion 2025-09-03T17:16:58+00:00 hourly 0.9 https://trial.medpath.com/news/savara-reports-50-increase-in-autoimmune-pap-patient-population-plans-december-2025-fda-resubmission-for-molbreevi 2025-09-03T17:15:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/savara-reports-50-increase-in-autoimmune-pap-patient-population-plans-december-2025-fda-resubmission-for-molbreevi 2025-09-03T17:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/lantern-pharma-receives-fda-guidance-for-pediatric-cns-cancer-trial-targeting-atrt 2025-09-03T17:15:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lantern-pharma-receives-fda-guidance-for-pediatric-cns-cancer-trial-targeting-atrt 2025-09-03T17:15:31+00:00 hourly 0.9 https://trial.medpath.com/news/splisense-achieves-first-positive-phase-2-results-for-inhaled-antisense-therapy-in-cystic-fibrosis 2025-09-03T17:15:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/splisense-achieves-first-positive-phase-2-results-for-inhaled-antisense-therapy-in-cystic-fibrosis 2025-09-03T17:15:28+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-secures-5-2-billion-licensing-deal-with-china-s-argo-for-rnai-cardiovascular-therapies 2025-09-03T17:15:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-secures-5-2-billion-licensing-deal-with-china-s-argo-for-rnai-cardiovascular-therapies 2025-09-03T17:15:14+00:00 hourly 0.9 https://trial.medpath.com/news/treeline-biosciences-initiates-three-phase-1-trials-targeting-bcl6-kras-and-ezh2-with-1-1b-in-total-funding 2025-09-03T17:11:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/treeline-biosciences-initiates-three-phase-1-trials-targeting-bcl6-kras-and-ezh2-with-1-1b-in-total-funding 2025-09-03T17:11:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-vaccine-advisory-panel-loses-prominent-expert-paul-offit-amid-kennedy-administration-changes 2025-09-03T17:11:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-vaccine-advisory-panel-loses-prominent-expert-paul-offit-amid-kennedy-administration-changes 2025-09-03T17:11:09+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-pharmaceutical-companies-pivot-from-weight-loss-drug-compounding-to-generic-development-as-fda-restrictions-tighten 2025-09-03T13:15:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-pharmaceutical-companies-pivot-from-weight-loss-drug-compounding-to-generic-development-as-fda-restrictions-tighten 2025-09-03T13:15:20+00:00 hourly 0.9 https://trial.medpath.com/news/argo-biopharma-and-novartis-expand-partnership-with-5-2-billion-cardiovascular-sirna-deal 2025-09-03T13:12:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/argo-biopharma-and-novartis-expand-partnership-with-5-2-billion-cardiovascular-sirna-deal 2025-09-03T13:12:55+00:00 hourly 0.9 https://trial.medpath.com/news/arcascience-secures-7m-to-accelerate-ai-driven-drug-safety-evaluation-platform 2025-09-03T13:11:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcascience-secures-7m-to-accelerate-ai-driven-drug-safety-evaluation-platform 2025-09-03T13:11:50+00:00 hourly 0.9 https://trial.medpath.com/news/resolution-therapeutics-doses-first-patient-with-engineered-macrophage-therapy-for-end-stage-liver-disease 2025-09-03T13:11:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/resolution-therapeutics-doses-first-patient-with-engineered-macrophage-therapy-for-end-stage-liver-disease 2025-09-03T13:11:39+00:00 hourly 0.9 https://trial.medpath.com/news/ideaya-biosciences-submits-ind-for-ide892-prmt5-inhibitor-targeting-mtap-deleted-lung-cancer 2025-09-03T13:11:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ideaya-biosciences-submits-ind-for-ide892-prmt5-inhibitor-targeting-mtap-deleted-lung-cancer 2025-09-03T13:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/nucana-to-present-preclinical-data-on-nuc-7738-and-pd-1-inhibitor-combination-at-esmo-2025 2025-09-03T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nucana-to-present-preclinical-data-on-nuc-7738-and-pd-1-inhibitor-combination-at-esmo-2025 2025-09-03T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/microbiotix-secures-krw-20-billion-series-b-to-launch-korea-s-first-bacteriophage-clinical-trial 2025-09-03T11:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microbiotix-secures-krw-20-billion-series-b-to-launch-korea-s-first-bacteriophage-clinical-trial 2025-09-03T11:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/alpha-tau-initiates-first-u-s-patient-treatment-in-pancreatic-cancer-trial-combining-alpha-dart-with-chemotherapy 2025-09-03T09:10:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alpha-tau-initiates-first-u-s-patient-treatment-in-pancreatic-cancer-trial-combining-alpha-dart-with-chemotherapy 2025-09-03T09:10:39+00:00 hourly 0.9 https://trial.medpath.com/news/bostongene-s-ai-model-identifies-five-novel-subtypes-to-predict-immunotherapy-response-in-kidney-cancer 2025-09-03T06:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bostongene-s-ai-model-identifies-five-novel-subtypes-to-predict-immunotherapy-response-in-kidney-cancer 2025-09-03T06:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/mainz-biomed-launches-coloalert-colorectal-cancer-screening-test-in-switzerland-following-regulatory-approval 2025-09-03T06:41:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mainz-biomed-launches-coloalert-colorectal-cancer-screening-test-in-switzerland-following-regulatory-approval 2025-09-03T06:41:36+00:00 hourly 0.9 https://trial.medpath.com/news/cml-treatment-revolution-from-deadly-disease-to-treatment-free-remission-in-25-years 2025-09-03T02:44:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cml-treatment-revolution-from-deadly-disease-to-treatment-free-remission-in-25-years 2025-09-03T02:44:41+00:00 hourly 0.9 https://trial.medpath.com/news/zeaxanthin-supplement-shows-promise-in-enhancing-cancer-immunotherapy-effectiveness 2025-09-03T01:15:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zeaxanthin-supplement-shows-promise-in-enhancing-cancer-immunotherapy-effectiveness 2025-09-03T01:15:10+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-gains-japanese-approval-for-symplicity-spyral-renal-denervation-system-to-treat-resistant-hypertension 2025-09-03T01:13:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-gains-japanese-approval-for-symplicity-spyral-renal-denervation-system-to-treat-resistant-hypertension 2025-09-03T01:13:06+00:00 hourly 0.9 https://trial.medpath.com/news/aptamer-and-invizius-partner-to-develop-next-generation-complement-system-therapies-using-synthetic-binders 2025-09-03T01:12:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptamer-and-invizius-partner-to-develop-next-generation-complement-system-therapies-using-synthetic-binders 2025-09-03T01:12:57+00:00 hourly 0.9 https://trial.medpath.com/news/cognition-therapeutics-secures-30-million-to-advance-alzheimer-s-drug-zervimesine-into-phase-3-development 2025-09-03T01:12:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cognition-therapeutics-secures-30-million-to-advance-alzheimer-s-drug-zervimesine-into-phase-3-development 2025-09-03T01:12:48+00:00 hourly 0.9 https://trial.medpath.com/news/new-found-gold-confirms-high-recovery-rates-in-phase-iii-metallurgical-testing-at-queensway-gold-project 2025-09-03T01:12:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-found-gold-confirms-high-recovery-rates-in-phase-iii-metallurgical-testing-at-queensway-gold-project 2025-09-03T01:12:38+00:00 hourly 0.9 https://trial.medpath.com/news/indian-scientists-develop-novel-organoselenium-compound-showing-promise-against-triple-negative-breast-cancer 2025-09-03T01:11:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indian-scientists-develop-novel-organoselenium-compound-showing-promise-against-triple-negative-breast-cancer 2025-09-03T01:11:41+00:00 hourly 0.9 https://trial.medpath.com/news/covid-19-infection-linked-to-49-higher-risk-of-depression-and-anxiety-in-school-age-children 2025-09-03T01:11:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/covid-19-infection-linked-to-49-higher-risk-of-depression-and-anxiety-in-school-age-children 2025-09-03T01:11:22+00:00 hourly 0.9 https://trial.medpath.com/news/nanoparticle-vaccines-show-promise-against-hpv-related-cancers-in-preclinical-studies 2025-09-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoparticle-vaccines-show-promise-against-hpv-related-cancers-in-preclinical-studies 2025-09-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/vcu-massey-and-md-anderson-researchers-launch-7-3m-clinical-trial-targeting-cancer-stem-cells-in-metastatic-triple-negative-breast-cancer 2025-09-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vcu-massey-and-md-anderson-researchers-launch-7-3m-clinical-trial-targeting-cancer-stem-cells-in-metastatic-triple-negative-breast-cancer 2025-09-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/chicago-hospitals-launch-first-of-its-kind-breast-cancer-research-consortium-for-advanced-er-her2-cases 2025-09-02T22:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chicago-hospitals-launch-first-of-its-kind-breast-cancer-research-consortium-for-advanced-er-her2-cases 2025-09-02T22:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/medical-care-technologies-develops-patent-pending-ai-platform-for-smartphone-based-health-screening 2025-09-02T21:19:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medical-care-technologies-develops-patent-pending-ai-platform-for-smartphone-based-health-screening 2025-09-02T21:19:57+00:00 hourly 0.9 https://trial.medpath.com/news/interferon-alpha-nasal-spray-reduces-covid-19-risk-by-40-in-cancer-patients 2025-09-02T21:17:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/interferon-alpha-nasal-spray-reduces-covid-19-risk-by-40-in-cancer-patients 2025-09-02T21:17:26+00:00 hourly 0.9 https://trial.medpath.com/news/medipal-holdings-and-jcr-pharmaceuticals-partner-on-novel-gm2-gangliosidosis-therapy-jr-479 2025-09-02T21:15:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medipal-holdings-and-jcr-pharmaceuticals-partner-on-novel-gm2-gangliosidosis-therapy-jr-479 2025-09-02T21:15:43+00:00 hourly 0.9 https://trial.medpath.com/news/seqone-acquires-congenica-to-create-global-leader-in-ai-powered-genomic-medicine 2025-09-02T21:15:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seqone-acquires-congenica-to-create-global-leader-in-ai-powered-genomic-medicine 2025-09-02T21:15:39+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-secures-200-million-novartis-deal-for-alpha-synuclein-sirna-therapy 2025-09-02T21:14:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrowhead-pharmaceuticals-secures-200-million-novartis-deal-for-alpha-synuclein-sirna-therapy 2025-09-02T21:14:14+00:00 hourly 0.9 https://trial.medpath.com/news/bridgebio-s-encaleret-achieves-calcium-normalization-in-80-of-post-surgical-hypoparathyroidism-patients 2025-09-02T21:13:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridgebio-s-encaleret-achieves-calcium-normalization-in-80-of-post-surgical-hypoparathyroidism-patients 2025-09-02T21:13:54+00:00 hourly 0.9 https://trial.medpath.com/news/geneseeq-secures-fda-510-k-clearance-for-comprehensive-425-gene-tumor-profiling-assay 2025-09-02T21:13:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geneseeq-secures-fda-510-k-clearance-for-comprehensive-425-gene-tumor-profiling-assay 2025-09-02T21:13:10+00:00 hourly 0.9 https://trial.medpath.com/news/repurposed-drugs-successfully-clear-dormant-breast-cancer-cells-in-groundbreaking-clinical-trial 2025-09-02T21:12:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repurposed-drugs-successfully-clear-dormant-breast-cancer-cells-in-groundbreaking-clinical-trial 2025-09-02T21:12:50+00:00 hourly 0.9 https://trial.medpath.com/news/ryvu-therapeutics-partners-with-biontech-to-accelerate-cancer-immunotherapy-trials-in-poland 2025-09-02T21:10:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ryvu-therapeutics-partners-with-biontech-to-accelerate-cancer-immunotherapy-trials-in-poland 2025-09-02T21:10:12+00:00 hourly 0.9 https://trial.medpath.com/news/azelastine-nasal-spray-shows-promise-in-preventing-covid-19-infections-in-clinical-trial 2025-09-02T21:09:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/azelastine-nasal-spray-shows-promise-in-preventing-covid-19-infections-in-clinical-trial 2025-09-02T21:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-s-varipulse-platform-achieves-99-7-effectiveness-with-zero-strokes-in-791-patient-atrial-fibrillation-study 2025-09-02T17:18:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-s-varipulse-platform-achieves-99-7-effectiveness-with-zero-strokes-in-791-patient-atrial-fibrillation-study 2025-09-02T17:18:47+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-pharmaceuticals-partners-with-enlaza-therapeutics-in-45-million-deal-to-develop-autoimmune-and-gene-editing-therapies 2025-09-02T17:18:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-pharmaceuticals-partners-with-enlaza-therapeutics-in-45-million-deal-to-develop-autoimmune-and-gene-editing-therapies 2025-09-02T17:18:45+00:00 hourly 0.9 https://trial.medpath.com/news/cnipa-upholds-astrazeneca-s-dapagliflozin-crystal-patent-in-landmark-swiss-type-claims-ruling 2025-09-02T17:17:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cnipa-upholds-astrazeneca-s-dapagliflozin-crystal-patent-in-landmark-swiss-type-claims-ruling 2025-09-02T17:17:43+00:00 hourly 0.9 https://trial.medpath.com/news/hoth-therapeutics-ht-kit-shows-promising-preclinical-results-in-kit-driven-cancers 2025-09-02T17:17:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hoth-therapeutics-ht-kit-shows-promising-preclinical-results-in-kit-driven-cancers 2025-09-02T17:17:35+00:00 hourly 0.9 https://trial.medpath.com/news/step-pharma-initiates-phase-1b-trial-of-dencatistat-for-essential-thrombocythaemia 2025-09-02T17:16:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/step-pharma-initiates-phase-1b-trial-of-dencatistat-for-essential-thrombocythaemia 2025-09-02T17:16:57+00:00 hourly 0.9 https://trial.medpath.com/news/iggenix-completes-enrollment-for-first-in-human-trial-of-novel-peanut-allergy-antibody-therapy 2025-09-02T17:16:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iggenix-completes-enrollment-for-first-in-human-trial-of-novel-peanut-allergy-antibody-therapy 2025-09-02T17:16:52+00:00 hourly 0.9 https://trial.medpath.com/news/neucore-bio-receives-350k-nih-grant-to-develop-exosome-based-gene-therapy-for-charcot-marie-tooth-disease 2025-09-02T17:16:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neucore-bio-receives-350k-nih-grant-to-develop-exosome-based-gene-therapy-for-charcot-marie-tooth-disease 2025-09-02T17:16:07+00:00 hourly 0.9 https://trial.medpath.com/news/exmoor-pharma-forms-strategic-partnerships-to-strengthen-uk-cell-and-gene-therapy-manufacturing-pipeline 2025-09-02T17:16:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exmoor-pharma-forms-strategic-partnerships-to-strengthen-uk-cell-and-gene-therapy-manufacturing-pipeline 2025-09-02T17:16:04+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-s-impella-cp-heart-pump-demonstrates-16-3-mortality-reduction-in-10-year-follow-up-study 2025-09-02T17:15:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-s-impella-cp-heart-pump-demonstrates-16-3-mortality-reduction-in-10-year-follow-up-study 2025-09-02T17:15:29+00:00 hourly 0.9 https://trial.medpath.com/news/nanoscope-s-mco-010-receives-fda-rmat-and-five-ema-orphan-designations-for-retinal-dystrophies 2025-09-02T17:14:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoscope-s-mco-010-receives-fda-rmat-and-five-ema-orphan-designations-for-retinal-dystrophies 2025-09-02T17:14:50+00:00 hourly 0.9 https://trial.medpath.com/news/kala-bio-names-todd-bazemore-as-permanent-ceo-ahead-of-pivotal-phase-2b-trial-readout 2025-09-02T17:14:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kala-bio-names-todd-bazemore-as-permanent-ceo-ahead-of-pivotal-phase-2b-trial-readout 2025-09-02T17:14:33+00:00 hourly 0.9 https://trial.medpath.com/news/aera-therapeutics-names-bill-querbes-as-chief-scientific-officer-to-advance-genetic-medicine-pipeline 2025-09-02T17:13:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aera-therapeutics-names-bill-querbes-as-chief-scientific-officer-to-advance-genetic-medicine-pipeline 2025-09-02T17:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-veterans-launch-corsera-health-with-annual-rnai-drug-to-prevent-cardiovascular-disease 2025-09-02T17:13:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-veterans-launch-corsera-health-with-annual-rnai-drug-to-prevent-cardiovascular-disease 2025-09-02T17:13:12+00:00 hourly 0.9 https://trial.medpath.com/news/quotient-sciences-and-cpi-form-joint-venture-to-accelerate-rna-drug-development-with-integrated-manufacturing-platform 2025-09-02T17:13:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quotient-sciences-and-cpi-form-joint-venture-to-accelerate-rna-drug-development-with-integrated-manufacturing-platform 2025-09-02T17:13:10+00:00 hourly 0.9 https://trial.medpath.com/news/alivamab-biologics-offers-royalty-free-access-to-transgenic-mouse-platform-for-human-antibody-discovery 2025-09-02T17:12:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alivamab-biologics-offers-royalty-free-access-to-transgenic-mouse-platform-for-human-antibody-discovery 2025-09-02T17:12:34+00:00 hourly 0.9 https://trial.medpath.com/news/dod-awards-963k-to-spri-for-breakthrough-extracellular-vesicle-study-in-osteoarthritis-treatment 2025-09-02T17:10:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dod-awards-963k-to-spri-for-breakthrough-extracellular-vesicle-study-in-osteoarthritis-treatment 2025-09-02T17:10:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-medtronic-s-minimed-780g-system-for-abbott-sensor-integration-and-type-2-diabetes-use 2025-09-02T17:10:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-medtronic-s-minimed-780g-system-for-abbott-sensor-integration-and-type-2-diabetes-use 2025-09-02T17:10:05+00:00 hourly 0.9 https://trial.medpath.com/news/predicine-initiates-fda-premarket-approval-application-for-bladder-cancer-companion-diagnostic 2025-09-02T17:10:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/predicine-initiates-fda-premarket-approval-application-for-bladder-cancer-companion-diagnostic 2025-09-02T17:10:03+00:00 hourly 0.9 https://trial.medpath.com/news/medical-horizons-partners-with-bowhead-health-to-expand-ai-powered-clinical-trial-matching-across-italy-turkey-and-cyprus 2025-09-02T17:09:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medical-horizons-partners-with-bowhead-health-to-expand-ai-powered-clinical-trial-matching-across-italy-turkey-and-cyprus 2025-09-02T17:09:46+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-launches-first-generic-eribulin-mesylate-injection-in-66-3-million-market 2025-09-02T17:09:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-launches-first-generic-eribulin-mesylate-injection-in-66-3-million-market 2025-09-02T17:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/zenas-biopharma-secures-300-million-royalty-deal-with-royalty-pharma-for-obexelimab-development 2025-09-02T17:09:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zenas-biopharma-secures-300-million-royalty-deal-with-royalty-pharma-for-obexelimab-development 2025-09-02T17:09:18+00:00 hourly 0.9 https://trial.medpath.com/news/vtv-therapeutics-raises-80-million-to-advance-phase-3-trial-of-type-1-diabetes-drug-cadisegliatin 2025-09-02T13:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vtv-therapeutics-raises-80-million-to-advance-phase-3-trial-of-type-1-diabetes-drug-cadisegliatin 2025-09-02T13:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-advances-cancer-drug-pipeline-with-unloxcyt-launch-planned-for-fy26 2025-09-02T13:21:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-advances-cancer-drug-pipeline-with-unloxcyt-launch-planned-for-fy26 2025-09-02T13:21:39+00:00 hourly 0.9 https://trial.medpath.com/news/genentech-partners-with-omass-therapeutics-in-400m-ibd-drug-development-deal 2025-09-02T13:16:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genentech-partners-with-omass-therapeutics-in-400m-ibd-drug-development-deal 2025-09-02T13:16:56+00:00 hourly 0.9 https://trial.medpath.com/news/spleen-targeted-mrna-vaccine-shows-promise-against-hepatocellular-carcinoma-in-preclinical-studies 2025-09-02T13:16:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spleen-targeted-mrna-vaccine-shows-promise-against-hepatocellular-carcinoma-in-preclinical-studies 2025-09-02T13:16:53+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-antibody-therapy-shows-promise-against-treatment-resistant-breast-cancer 2025-09-02T13:16:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-antibody-therapy-shows-promise-against-treatment-resistant-breast-cancer 2025-09-02T13:16:19+00:00 hourly 0.9 https://trial.medpath.com/news/obi-pharma-initiates-phase-1-2-trial-for-novel-trop2-targeted-adc-obi-902-in-advanced-solid-tumors 2025-09-02T13:16:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/obi-pharma-initiates-phase-1-2-trial-for-novel-trop2-targeted-adc-obi-902-in-advanced-solid-tumors 2025-09-02T13:16:14+00:00 hourly 0.9 https://trial.medpath.com/news/olema-oncology-and-pfizer-launch-phase-1b-2-trial-combining-palazestrant-with-atirmociclib-for-er-her2-metastatic-breast-cancer 2025-09-02T13:16:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olema-oncology-and-pfizer-launch-phase-1b-2-trial-combining-palazestrant-with-atirmociclib-for-er-her2-metastatic-breast-cancer 2025-09-02T13:16:12+00:00 hourly 0.9 https://trial.medpath.com/news/charm-therapeutics-raises-80m-to-advance-ai-designed-menin-inhibitor-for-aml-treatment 2025-09-02T13:15:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/charm-therapeutics-raises-80m-to-advance-ai-designed-menin-inhibitor-for-aml-treatment 2025-09-02T13:15:03+00:00 hourly 0.9 https://trial.medpath.com/news/novaremed-completes-patient-enrollment-in-nih-funded-phase-2b-trial-of-non-opioid-nispomeben-for-diabetic-neuropathy-pain 2025-09-02T13:15:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novaremed-completes-patient-enrollment-in-nih-funded-phase-2b-trial-of-non-opioid-nispomeben-for-diabetic-neuropathy-pain 2025-09-02T13:15:01+00:00 hourly 0.9 https://trial.medpath.com/news/encoded-therapeutics-receives-fda-rmat-designation-for-etx101-gene-therapy-in-dravet-syndrome 2025-09-02T13:14:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/encoded-therapeutics-receives-fda-rmat-designation-for-etx101-gene-therapy-in-dravet-syndrome 2025-09-02T13:14:53+00:00 hourly 0.9 https://trial.medpath.com/news/terumo-bct-and-pwc-belgium-launch-initiative-to-address-limited-access-to-advanced-cell-and-gene-therapies-in-europe 2025-09-02T13:14:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/terumo-bct-and-pwc-belgium-launch-initiative-to-address-limited-access-to-advanced-cell-and-gene-therapies-in-europe 2025-09-02T13:14:47+00:00 hourly 0.9 https://trial.medpath.com/news/zymeworks-discontinues-zw171-mesothelin-targeted-t-cell-engager-after-phase-1-safety-concerns 2025-09-02T13:13:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zymeworks-discontinues-zw171-mesothelin-targeted-t-cell-engager-after-phase-1-safety-concerns 2025-09-02T13:13:53+00:00 hourly 0.9 https://trial.medpath.com/news/nano-nuclear-energy-secures-1-25m-afwerx-contract-for-military-microreactor-deployment-study 2025-09-02T13:13:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nano-nuclear-energy-secures-1-25m-afwerx-contract-for-military-microreactor-deployment-study 2025-09-02T13:13:30+00:00 hourly 0.9 https://trial.medpath.com/news/servier-and-ideaya-biosciences-strike-530m-partnership-for-uveal-melanoma-drug-darovasertib 2025-09-02T13:12:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/servier-and-ideaya-biosciences-strike-530m-partnership-for-uveal-melanoma-drug-darovasertib 2025-09-02T13:12:25+00:00 hourly 0.9 https://trial.medpath.com/news/united-therapeutics-tyvaso-meets-primary-endpoint-in-phase-3-ipf-trial-demonstrating-significant-lung-function-improvement 2025-09-02T13:10:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/united-therapeutics-tyvaso-meets-primary-endpoint-in-phase-3-ipf-trial-demonstrating-significant-lung-function-improvement 2025-09-02T13:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/hemex-expands-global-clinical-network-alliance-to-strengthen-end-to-end-cro-capabilities 2025-09-02T13:10:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hemex-expands-global-clinical-network-alliance-to-strengthen-end-to-end-cro-capabilities 2025-09-02T13:10:09+00:00 hourly 0.9 https://trial.medpath.com/news/pharming-group-appoints-kenneth-lynard-as-chief-financial-officer-to-strengthen-rare-disease-growth-strategy 2025-09-02T09:13:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharming-group-appoints-kenneth-lynard-as-chief-financial-officer-to-strengthen-rare-disease-growth-strategy 2025-09-02T09:13:46+00:00 hourly 0.9 https://trial.medpath.com/news/brenus-pharma-initiates-first-in-human-trial-of-stc-1010-immunotherapy-for-advanced-colorectal-cancer 2025-09-02T09:11:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brenus-pharma-initiates-first-in-human-trial-of-stc-1010-immunotherapy-for-advanced-colorectal-cancer 2025-09-02T09:11:27+00:00 hourly 0.9 https://trial.medpath.com/news/citryll-initiates-phase-iia-trial-of-first-in-class-net-targeting-antibody-cit-013-for-rheumatoid-arthritis 2025-09-02T09:11:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/citryll-initiates-phase-iia-trial-of-first-in-class-net-targeting-antibody-cit-013-for-rheumatoid-arthritis 2025-09-02T09:11:16+00:00 hourly 0.9 https://trial.medpath.com/news/lantheus-advances-dual-alzheimer-s-diagnostic-strategy-with-tau-and-beta-amyloid-pet-imaging-agents 2025-09-02T09:09:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lantheus-advances-dual-alzheimer-s-diagnostic-strategy-with-tau-and-beta-amyloid-pet-imaging-agents 2025-09-02T09:09:15+00:00 hourly 0.9 https://trial.medpath.com/news/qiagen-receives-fda-clearance-for-high-throughput-qiastat-dx-rise-syndromic-testing-system 2025-09-02T09:08:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qiagen-receives-fda-clearance-for-high-throughput-qiastat-dx-rise-syndromic-testing-system 2025-09-02T09:08:56+00:00 hourly 0.9 https://trial.medpath.com/news/hengrui-medicine-receives-china-s-first-ezh2-inhibitor-approval-for-hematological-malignancies 2025-09-02T06:40:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hengrui-medicine-receives-china-s-first-ezh2-inhibitor-approval-for-hematological-malignancies 2025-09-02T06:40:43+00:00 hourly 0.9 https://trial.medpath.com/news/nsclc-molecular-testing-faces-critical-barriers-as-targeted-therapies-expand 2025-09-02T06:39:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nsclc-molecular-testing-faces-critical-barriers-as-targeted-therapies-expand 2025-09-02T06:39:53+00:00 hourly 0.9 https://trial.medpath.com/news/strata-excimer-laser-combined-with-jak-inhibitors-shows-100-response-rate-in-251-patient-vitiligo-trial 2025-09-02T05:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strata-excimer-laser-combined-with-jak-inhibitors-shows-100-response-rate-in-251-patient-vitiligo-trial 2025-09-02T05:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaceutical-industry-accelerates-sustainable-packaging-adoption-as-environmental-pressures-mount 2025-09-02T02:48:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmaceutical-industry-accelerates-sustainable-packaging-adoption-as-environmental-pressures-mount 2025-09-02T02:48:08+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-university-launches-ps118m-ai-powered-vaccine-research-program-against-antibiotic-resistant-bacteria 2025-09-02T01:13:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-university-launches-ps118m-ai-powered-vaccine-research-program-against-antibiotic-resistant-bacteria 2025-09-02T01:13:02+00:00 hourly 0.9 https://trial.medpath.com/news/mission-hospital-completes-first-in-human-trial-of-emstop-stroke-prevention-device-for-heart-valve-surgery 2025-09-02T01:12:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mission-hospital-completes-first-in-human-trial-of-emstop-stroke-prevention-device-for-heart-valve-surgery 2025-09-02T01:12:52+00:00 hourly 0.9 https://trial.medpath.com/news/oslo-university-hospital-launches-phase-2-trial-comparing-ilb-r-to-standard-als-treatment 2025-09-02T01:12:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oslo-university-hospital-launches-phase-2-trial-comparing-ilb-r-to-standard-als-treatment 2025-09-02T01:12:27+00:00 hourly 0.9 https://trial.medpath.com/news/hydrogel-based-mrna-cancer-vaccine-platform-shows-promise-for-enhanced-immune-response 2025-09-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hydrogel-based-mrna-cancer-vaccine-platform-shows-promise-for-enhanced-immune-response 2025-09-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/stem-cell-derived-young-immune-cells-reverse-alzheimer-s-and-aging-signs-in-preclinical-study 2025-09-01T21:10:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stem-cell-derived-young-immune-cells-reverse-alzheimer-s-and-aging-signs-in-preclinical-study 2025-09-01T21:10:40+00:00 hourly 0.9 https://trial.medpath.com/news/intellia-therapeutics-gains-momentum-as-ark-invest-and-institutional-investors-back-crispr-gene-editing-platform 2025-09-01T21:10:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intellia-therapeutics-gains-momentum-as-ark-invest-and-institutional-investors-back-crispr-gene-editing-platform 2025-09-01T21:10:14+00:00 hourly 0.9 https://trial.medpath.com/news/nfl-biosciences-nfl-101-demonstrates-significant-efficacy-in-phase-ii-smoking-cessation-trial 2025-09-01T21:10:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nfl-biosciences-nfl-101-demonstrates-significant-efficacy-in-phase-ii-smoking-cessation-trial 2025-09-01T21:10:03+00:00 hourly 0.9 https://trial.medpath.com/news/tacsi-trial-challenges-dual-antiplatelet-therapy-after-cabg-shows-no-benefit-over-aspirin-alone 2025-09-01T21:09:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tacsi-trial-challenges-dual-antiplatelet-therapy-after-cabg-shows-no-benefit-over-aspirin-alone 2025-09-01T21:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/trump-demands-covid-19-drug-data-transparency-as-cdc-leadership-crisis-deepens 2025-09-01T21:08:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-demands-covid-19-drug-data-transparency-as-cdc-leadership-crisis-deepens 2025-09-01T21:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-partners-with-apollo-clinics-to-launch-comprehensive-obesity-management-programme-across-india 2025-09-01T17:16:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-partners-with-apollo-clinics-to-launch-comprehensive-obesity-management-programme-across-india 2025-09-01T17:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/high-court-strikes-out-sandoz-s-ps3-9-million-profit-claim-against-bayer-in-rivaroxaban-patent-dispute 2025-09-01T17:13:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-court-strikes-out-sandoz-s-ps3-9-million-profit-claim-against-bayer-in-rivaroxaban-patent-dispute 2025-09-01T17:13:54+00:00 hourly 0.9 https://trial.medpath.com/news/immupharma-files-groundbreaking-patent-for-p140-immunormalizer-targeting-type-m-immune-disorder 2025-09-01T17:11:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immupharma-files-groundbreaking-patent-for-p140-immunormalizer-targeting-type-m-immune-disorder 2025-09-01T17:11:07+00:00 hourly 0.9 https://trial.medpath.com/news/pharma-equity-group-receives-regulatory-approval-for-phase-ii-trial-of-rnx-011-in-secondary-peritonitis 2025-09-01T17:10:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharma-equity-group-receives-regulatory-approval-for-phase-ii-trial-of-rnx-011-in-secondary-peritonitis 2025-09-01T17:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-first-ever-waiver-of-clinical-efficacy-studies-for-monoclonal-antibody-biosimilars 2025-09-01T17:08:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-first-ever-waiver-of-clinical-efficacy-studies-for-monoclonal-antibody-biosimilars 2025-09-01T17:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/shanghai-henlius-biotech-receives-fda-approval-for-two-denosumab-biosimilars-for-osteoporosis-treatment 2025-09-01T17:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shanghai-henlius-biotech-receives-fda-approval-for-two-denosumab-biosimilars-for-osteoporosis-treatment 2025-09-01T17:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-shows-promise-for-small-cell-carcinoma-of-the-esophagus-dual-center-study-reveals 2025-09-01T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunotherapy-shows-promise-for-small-cell-carcinoma-of-the-esophagus-dual-center-study-reveals 2025-09-01T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mexico-s-patent-office-includes-second-use-pharmaceutical-patents-in-linkage-gazette-for-first-time 2025-09-01T13:19:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mexico-s-patent-office-includes-second-use-pharmaceutical-patents-in-linkage-gazette-for-first-time 2025-09-01T13:19:30+00:00 hourly 0.9 https://trial.medpath.com/news/cyted-health-secures-eur37-5m-series-b-to-advance-esophageal-cancer-diagnostics-platform 2025-09-01T13:17:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cyted-health-secures-eur37-5m-series-b-to-advance-esophageal-cancer-diagnostics-platform 2025-09-01T13:17:27+00:00 hourly 0.9 https://trial.medpath.com/news/sacubitril-valsartan-shows-superior-efficacy-over-enalapril-in-first-prospective-trial-for-chagas-disease-heart-failure 2025-09-01T13:16:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sacubitril-valsartan-shows-superior-efficacy-over-enalapril-in-first-prospective-trial-for-chagas-disease-heart-failure 2025-09-01T13:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/saudi-us-collaboration-develops-smart-multi-compartment-capsule-for-personalized-drug-delivery 2025-09-01T13:16:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/saudi-us-collaboration-develops-smart-multi-compartment-capsule-for-personalized-drug-delivery 2025-09-01T13:16:02+00:00 hourly 0.9 https://trial.medpath.com/news/eurofins-viracor-biopharma-expands-operations-with-new-96000-sq-ft-state-of-the-art-facility 2025-09-01T13:14:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eurofins-viracor-biopharma-expands-operations-with-new-96000-sq-ft-state-of-the-art-facility 2025-09-01T13:14:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-first-non-invasive-surrogate-endpoint-for-mash-clinical-trials 2025-09-01T13:14:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-first-non-invasive-surrogate-endpoint-for-mash-clinical-trials 2025-09-01T13:14:42+00:00 hourly 0.9 https://trial.medpath.com/news/island-pharmaceuticals-secures-fda-meeting-for-galidesivir-fast-track-approval-under-animal-rule-pathway 2025-09-01T13:13:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/island-pharmaceuticals-secures-fda-meeting-for-galidesivir-fast-track-approval-under-animal-rule-pathway 2025-09-01T13:13:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-weekly-autoinjector-for-eisai-s-alzheimer-s-drug-leqembi-enabling-at-home-treatment 2025-09-01T13:13:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-weekly-autoinjector-for-eisai-s-alzheimer-s-drug-leqembi-enabling-at-home-treatment 2025-09-01T13:13:07+00:00 hourly 0.9 https://trial.medpath.com/news/uk-drug-pricing-negotiations-collapse-threatening-access-to-innovative-medicines 2025-09-01T13:11:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-drug-pricing-negotiations-collapse-threatening-access-to-innovative-medicines 2025-09-01T13:11:40+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-data-confirms-pepaxti-efficacy-in-heavily-pretreated-multiple-myeloma-patients 2025-09-01T09:11:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-data-confirms-pepaxti-efficacy-in-heavily-pretreated-multiple-myeloma-patients 2025-09-01T09:11:23+00:00 hourly 0.9 https://trial.medpath.com/news/searle-secures-pakistani-regulatory-approval-for-denosumab-biosimilar-injections 2025-09-01T09:10:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/searle-secures-pakistani-regulatory-approval-for-denosumab-biosimilar-injections 2025-09-01T09:10:57+00:00 hourly 0.9 https://trial.medpath.com/news/tme-pharma-secures-eur2-35m-in-funding-to-advance-cancer-and-eye-disease-therapies 2025-09-01T09:10:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tme-pharma-secures-eur2-35m-in-funding-to-advance-cancer-and-eye-disease-therapies 2025-09-01T09:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/biophytis-advances-bio101-into-phase-2-obesity-trial-targeting-muscle-wasting-in-164-patients 2025-09-01T09:09:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biophytis-advances-bio101-into-phase-2-obesity-trial-targeting-muscle-wasting-in-164-patients 2025-09-01T09:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/alone-af-trial-shows-discontinuing-anticoagulants-after-successful-afib-ablation-reduces-bleeding-risk 2025-09-01T01:29:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alone-af-trial-shows-discontinuing-anticoagulants-after-successful-afib-ablation-reduces-bleeding-risk 2025-09-01T01:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/medpacto-s-vactosertib-achieves-complete-remission-in-osteosarcoma-phase-2-trial 2025-09-01T01:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medpacto-s-vactosertib-achieves-complete-remission-in-osteosarcoma-phase-2-trial 2025-09-01T01:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/remote-ecg-patch-screening-shows-modest-increase-in-atrial-fibrillation-detection-in-high-risk-older-adults 2025-08-31T21:34:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remote-ecg-patch-screening-shows-modest-increase-in-atrial-fibrillation-detection-in-high-risk-older-adults 2025-08-31T21:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-presents-comprehensive-epilepsy-research-portfolio-at-international-epilepsy-congress-2025 2025-08-31T21:27:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucb-presents-comprehensive-epilepsy-research-portfolio-at-international-epilepsy-congress-2025 2025-08-31T21:27:49+00:00 hourly 0.9 https://trial.medpath.com/news/conavi-medical-submits-next-generation-hybrid-imaging-system-to-fda-for-coronary-applications 2025-08-31T17:10:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/conavi-medical-submits-next-generation-hybrid-imaging-system-to-fda-for-coronary-applications 2025-08-31T17:10:15+00:00 hourly 0.9 https://trial.medpath.com/news/arcturus-therapeutics-advances-mrna-therapeutics-pipeline-with-strong-financial-performance-and-strategic-focus 2025-08-31T17:08:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcturus-therapeutics-advances-mrna-therapeutics-pipeline-with-strong-financial-performance-and-strategic-focus 2025-08-31T17:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-achieves-phase-iii-success-for-ianalumab-in-sjogren-s-disease-marking-potential-first-targeted-treatment 2025-08-31T17:08:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-achieves-phase-iii-success-for-ianalumab-in-sjogren-s-disease-marking-potential-first-targeted-treatment 2025-08-31T17:08:40+00:00 hourly 0.9 https://trial.medpath.com/news/tenaya-therapeutics-reveals-critical-risk-factors-in-largest-pediatric-mybpc3-associated-hcm-study 2025-08-31T17:08:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tenaya-therapeutics-reveals-critical-risk-factors-in-largest-pediatric-mybpc3-associated-hcm-study 2025-08-31T17:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/japan-approves-first-over-the-counter-emergency-contraceptive-pill-after-years-of-regulatory-delays 2025-08-31T17:06:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-approves-first-over-the-counter-emergency-contraceptive-pill-after-years-of-regulatory-delays 2025-08-31T17:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/statins-show-promise-as-repurposed-therapy-for-colorectal-cancer-treatment 2025-08-31T13:28:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/statins-show-promise-as-repurposed-therapy-for-colorectal-cancer-treatment 2025-08-31T13:28:21+00:00 hourly 0.9 https://trial.medpath.com/news/wegovy-shows-57-greater-cardiovascular-risk-reduction-compared-to-tirzepatide-in-real-world-study 2025-08-31T13:24:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wegovy-shows-57-greater-cardiovascular-risk-reduction-compared-to-tirzepatide-in-real-world-study 2025-08-31T13:24:15+00:00 hourly 0.9 https://trial.medpath.com/news/swedepad-trials-show-drug-coated-devices-fail-to-improve-key-outcomes-in-peripheral-artery-disease 2025-08-31T09:22:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/swedepad-trials-show-drug-coated-devices-fail-to-improve-key-outcomes-in-peripheral-artery-disease 2025-08-31T09:22:36+00:00 hourly 0.9 https://trial.medpath.com/news/neurotech-s-nti164-cannabinoid-therapy-shows-promise-in-pediatric-neurological-disorders-with-positive-phase-ii-iii-data 2025-08-31T09:22:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurotech-s-nti164-cannabinoid-therapy-shows-promise-in-pediatric-neurological-disorders-with-positive-phase-ii-iii-data 2025-08-31T09:22:27+00:00 hourly 0.9 https://trial.medpath.com/news/immuron-reports-record-sales-growth-and-advances-multiple-clinical-programs-for-infectious-disease-treatments 2025-08-31T09:20:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immuron-reports-record-sales-growth-and-advances-multiple-clinical-programs-for-infectious-disease-treatments 2025-08-31T09:20:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-pfizer-biontech-lp-8-1-adapted-covid-19-vaccine-for-high-risk-populations 2025-08-31T09:20:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-pfizer-biontech-lp-8-1-adapted-covid-19-vaccine-for-high-risk-populations 2025-08-31T09:20:50+00:00 hourly 0.9 https://trial.medpath.com/news/shorter-dual-antiplatelet-therapy-shows-promise-in-heart-attack-patients-two-major-trials-challenge-current-guidelines 2025-08-31T09:20:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shorter-dual-antiplatelet-therapy-shows-promise-in-heart-attack-patients-two-major-trials-challenge-current-guidelines 2025-08-31T09:20:40+00:00 hourly 0.9 https://trial.medpath.com/news/pharmacists-emerge-as-key-players-in-combating-vaccine-hesitancy-through-trust-building-and-clear-communication 2025-08-31T03:00:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmacists-emerge-as-key-players-in-combating-vaccine-hesitancy-through-trust-building-and-clear-communication 2025-08-31T03:00:27+00:00 hourly 0.9 https://trial.medpath.com/news/medicaid-cuts-could-disrupt-pediatric-healthcare-access-amid-eligibility-confusion 2025-08-31T03:00:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicaid-cuts-could-disrupt-pediatric-healthcare-access-amid-eligibility-confusion 2025-08-31T03:00:22+00:00 hourly 0.9 https://trial.medpath.com/news/ivabradine-fails-to-prevent-myocardial-injury-after-noncardiac-surgery-in-prevent-mins-trial 2025-08-31T01:24:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ivabradine-fails-to-prevent-myocardial-injury-after-noncardiac-surgery-in-prevent-mins-trial 2025-08-31T01:24:10+00:00 hourly 0.9 https://trial.medpath.com/news/foresight-diagnostics-and-roche-resolve-patent-dispute-with-phased-seq-licensing-agreement-for-non-hodgkin-s-lymphoma-diagnostics 2025-08-31T01:23:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/foresight-diagnostics-and-roche-resolve-patent-dispute-with-phased-seq-licensing-agreement-for-non-hodgkin-s-lymphoma-diagnostics 2025-08-31T01:23:24+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharmacy-chains-limit-covid-19-vaccine-access-following-fda-approval-of-2025-2026-formulation 2025-08-30T21:17:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-pharmacy-chains-limit-covid-19-vaccine-access-following-fda-approval-of-2025-2026-formulation 2025-08-30T21:17:44+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-appoints-hematology-leader-anas-younes-as-chief-medical-officer 2025-08-30T21:16:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-appoints-hematology-leader-anas-younes-as-chief-medical-officer 2025-08-30T21:16:07+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-receives-cdsco-approval-for-phase-iv-trial-of-high-dose-esomeprazole-dual-release-formulation 2025-08-30T21:15:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-receives-cdsco-approval-for-phase-iv-trial-of-high-dose-esomeprazole-dual-release-formulation 2025-08-30T21:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/daiichi-sankyo-initiates-development-of-triple-combination-lipid-lowering-tablet-to-address-treatment-gaps 2025-08-30T21:14:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daiichi-sankyo-initiates-development-of-triple-combination-lipid-lowering-tablet-to-address-treatment-gaps 2025-08-30T21:14:10+00:00 hourly 0.9 https://trial.medpath.com/news/conflicting-results-emerge-from-large-scale-high-dose-influenza-vaccine-studies-in-older-adults 2025-08-30T21:11:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/conflicting-results-emerge-from-large-scale-high-dose-influenza-vaccine-studies-in-older-adults 2025-08-30T21:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/altamira-therapeutics-advances-rna-delivery-platform-through-strategic-spin-off-and-circular-rna-innovation 2025-08-30T17:10:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/altamira-therapeutics-advances-rna-delivery-platform-through-strategic-spin-off-and-circular-rna-innovation 2025-08-30T17:10:53+00:00 hourly 0.9 https://trial.medpath.com/news/dapa-act-hf-timi-68-trial-shows-promise-for-in-hospital-sglt2-inhibitor-initiation-despite-missing-primary-endpoint 2025-08-30T17:10:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dapa-act-hf-timi-68-trial-shows-promise-for-in-hospital-sglt2-inhibitor-initiation-despite-missing-primary-endpoint 2025-08-30T17:10:51+00:00 hourly 0.9 https://trial.medpath.com/news/alnylam-advances-heart-drug-zilebesiran-to-phase-3-trial-despite-mid-stage-statistical-miss 2025-08-30T17:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alnylam-advances-heart-drug-zilebesiran-to-phase-3-trial-despite-mid-stage-statistical-miss 2025-08-30T17:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/alnylam-s-zilebesiran-advances-to-phase-iii-zenith-trial-for-hypertension-treatment 2025-08-30T17:07:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alnylam-s-zilebesiran-advances-to-phase-iii-zenith-trial-for-hypertension-treatment 2025-08-30T17:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/conflicting-beta-blocker-trial-results-challenge-standard-heart-attack-treatment-guidelines 2025-08-30T17:07:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/conflicting-beta-blocker-trial-results-challenge-standard-heart-attack-treatment-guidelines 2025-08-30T17:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/roche-and-alnylam-advance-zilebesiran-to-phase-iii-cardiovascular-outcomes-trial-following-positive-kardia-3-results 2025-08-30T17:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-and-alnylam-advance-zilebesiran-to-phase-iii-cardiovascular-outcomes-trial-following-positive-kardia-3-results 2025-08-30T17:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/olezarsen-achieves-60-triglyceride-reduction-in-phase-3-trial-for-cardiovascular-risk-patients 2025-08-30T17:07:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olezarsen-achieves-60-triglyceride-reduction-in-phase-3-trial-for-cardiovascular-risk-patients 2025-08-30T17:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-evidence-demonstrates-superior-cardiovascular-and-renal-benefits-of-glp-1-receptor-agonists-in-high-risk-patients 2025-08-30T17:06:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-evidence-demonstrates-superior-cardiovascular-and-renal-benefits-of-glp-1-receptor-agonists-in-high-risk-patients 2025-08-30T17:06:13+00:00 hourly 0.9 https://trial.medpath.com/news/exercise-and-cognitive-behavioral-therapy-show-promise-for-treating-broken-heart-syndrome-in-world-first-trial 2025-08-30T13:25:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exercise-and-cognitive-behavioral-therapy-show-promise-for-treating-broken-heart-syndrome-in-world-first-trial 2025-08-30T13:25:01+00:00 hourly 0.9 https://trial.medpath.com/news/aurobindo-pharma-subsidiaries-receive-mixed-fda-inspection-results-with-vai-classification-for-api-facility 2025-08-30T13:23:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aurobindo-pharma-subsidiaries-receive-mixed-fda-inspection-results-with-vai-classification-for-api-facility 2025-08-30T13:23:59+00:00 hourly 0.9 https://trial.medpath.com/news/teva-receives-fda-approval-for-generic-saxenda-targeting-165-million-weight-management-market 2025-08-30T13:23:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teva-receives-fda-approval-for-generic-saxenda-targeting-165-million-weight-management-market 2025-08-30T13:23:10+00:00 hourly 0.9 https://trial.medpath.com/news/mavacamten-fails-to-show-significant-benefit-in-non-obstructive-hypertrophic-cardiomyopathy-trial 2025-08-30T09:22:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mavacamten-fails-to-show-significant-benefit-in-non-obstructive-hypertrophic-cardiomyopathy-trial 2025-08-30T09:22:19+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-therapeutics-cdmo-market-projected-to-reach-9-billion-by-2030-amid-growing-demand-for-specialized-manufacturing 2025-08-30T05:28:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrna-therapeutics-cdmo-market-projected-to-reach-9-billion-by-2030-amid-growing-demand-for-specialized-manufacturing 2025-08-30T05:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/yd-bio-limited-goes-public-on-nasdaq-advancing-dna-methylation-cancer-detection-and-exosome-therapies 2025-08-30T05:21:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yd-bio-limited-goes-public-on-nasdaq-advancing-dna-methylation-cancer-detection-and-exosome-therapies 2025-08-30T05:21:36+00:00 hourly 0.9 https://trial.medpath.com/news/india-streamlines-drug-development-process-with-digital-applications-and-faster-approval-timelines 2025-08-30T05:21:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-streamlines-drug-development-process-with-digital-applications-and-faster-approval-timelines 2025-08-30T05:21:33+00:00 hourly 0.9 https://trial.medpath.com/news/exelixis-promotes-dana-aftab-to-lead-consolidated-r-d-operations-amid-strategic-restructuring 2025-08-30T05:20:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exelixis-promotes-dana-aftab-to-lead-consolidated-r-d-operations-amid-strategic-restructuring 2025-08-30T05:20:23+00:00 hourly 0.9 https://trial.medpath.com/news/india-reports-1705-clinical-trial-deaths-since-2021-as-safety-concerns-mount 2025-08-30T05:19:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-reports-1705-clinical-trial-deaths-since-2021-as-safety-concerns-mount 2025-08-30T05:19:50+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-guselkumab-for-moderate-to-severe-ulcerative-colitis-and-crohn-s-disease 2025-08-30T01:33:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-approves-guselkumab-for-moderate-to-severe-ulcerative-colitis-and-crohn-s-disease 2025-08-30T01:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-challenges-ars-pharmaceuticals-neffy-patents-with-generic-application-filing 2025-08-30T01:29:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-challenges-ars-pharmaceuticals-neffy-patents-with-generic-application-filing 2025-08-30T01:29:06+00:00 hourly 0.9 https://trial.medpath.com/news/cyted-health-secures-44m-series-b-to-expand-esophageal-cancer-diagnostics-platform-in-us-market 2025-08-30T01:26:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cyted-health-secures-44m-series-b-to-expand-esophageal-cancer-diagnostics-platform-in-us-market 2025-08-30T01:26:22+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-wayrilz-becomes-first-btk-inhibitor-approved-for-immune-thrombocytopenia-treatment 2025-08-30T01:22:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-s-wayrilz-becomes-first-btk-inhibitor-approved-for-immune-thrombocytopenia-treatment 2025-08-30T01:22:46+00:00 hourly 0.9 https://trial.medpath.com/news/axsome-submits-fda-application-for-axs-05-in-alzheimer-s-disease-agitation-following-positive-phase-3-results 2025-08-30T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axsome-submits-fda-application-for-axs-05-in-alzheimer-s-disease-agitation-following-positive-phase-3-results 2025-08-30T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/bempedoic-acid-receives-highest-esc-eas-guideline-recommendation-for-cardiovascular-risk-reduction 2025-08-29T21:24:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bempedoic-acid-receives-highest-esc-eas-guideline-recommendation-for-cardiovascular-risk-reduction 2025-08-29T21:24:42+00:00 hourly 0.9 https://trial.medpath.com/news/sycamore-partners-completes-11-45-per-share-acquisition-of-walgreens-boots-alliance 2025-08-29T21:24:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sycamore-partners-completes-11-45-per-share-acquisition-of-walgreens-boots-alliance 2025-08-29T21:24:39+00:00 hourly 0.9 https://trial.medpath.com/news/liposome-development-services-market-projected-to-reach-2-34-billion-by-2035-as-drug-delivery-challenges-drive-industry-growth 2025-08-29T21:20:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liposome-development-services-market-projected-to-reach-2-34-billion-by-2035-as-drug-delivery-challenges-drive-industry-growth 2025-08-29T21:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/phase-4-trial-demonstrates-superior-efficacy-of-endoscopic-sinus-surgery-over-antibiotics-for-chronic-rhinosinusitis 2025-08-29T21:19:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-4-trial-demonstrates-superior-efficacy-of-endoscopic-sinus-surgery-over-antibiotics-for-chronic-rhinosinusitis 2025-08-29T21:19:36+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-receives-fda-orphan-drug-designation-for-autosomal-dominant-polycystic-kidney-disease-treatment 2025-08-29T21:16:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-receives-fda-orphan-drug-designation-for-autosomal-dominant-polycystic-kidney-disease-treatment 2025-08-29T21:16:15+00:00 hourly 0.9 https://trial.medpath.com/news/korean-hair-loss-shampoo-becomes-first-to-gain-chinese-regulatory-approval 2025-08-29T21:15:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/korean-hair-loss-shampoo-becomes-first-to-gain-chinese-regulatory-approval 2025-08-29T21:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/indena-and-tcg-greenchem-form-strategic-alliance-to-accelerate-adc-payload-linker-development 2025-08-29T21:15:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indena-and-tcg-greenchem-form-strategic-alliance-to-accelerate-adc-payload-linker-development 2025-08-29T21:15:42+00:00 hourly 0.9 https://trial.medpath.com/news/lubiprostone-shows-promise-in-slowing-kidney-function-decline-in-phase-ii-ckd-trial 2025-08-29T21:14:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lubiprostone-shows-promise-in-slowing-kidney-function-decline-in-phase-ii-ckd-trial 2025-08-29T21:14:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-medtronic-s-evolut-tavr-systems-for-expanded-redo-tavr-indication 2025-08-29T21:12:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-medtronic-s-evolut-tavr-systems-for-expanded-redo-tavr-indication 2025-08-29T21:12:08+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-develops-off-the-shelf-car-nkt-cell-therapy-for-metastatic-kidney-cancer 2025-08-29T16:58:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucla-develops-off-the-shelf-car-nkt-cell-therapy-for-metastatic-kidney-cancer 2025-08-29T16:58:20+00:00 hourly 0.9 https://trial.medpath.com/news/nyu-researchers-develop-wireless-led-pill-for-non-invasive-gut-nerve-stimulation 2025-08-29T16:58:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nyu-researchers-develop-wireless-led-pill-for-non-invasive-gut-nerve-stimulation 2025-08-29T16:58:09+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-partners-with-jd-health-for-direct-to-consumer-glp-1-drug-sales-in-china 2025-08-29T16:57:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-partners-with-jd-health-for-direct-to-consumer-glp-1-drug-sales-in-china 2025-08-29T16:57:36+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-evidence-confirms-mepolizumab-s-efficacy-in-severe-eosinophilic-asthma-with-enhanced-benefits-for-comorbid-nasal-polyps 2025-08-29T16:57:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-evidence-confirms-mepolizumab-s-efficacy-in-severe-eosinophilic-asthma-with-enhanced-benefits-for-comorbid-nasal-polyps 2025-08-29T16:57:27+00:00 hourly 0.9 https://trial.medpath.com/news/neogenomics-wins-patent-dispute-against-natera-clears-path-for-radar-st-assay-commercialization 2025-08-29T16:57:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neogenomics-wins-patent-dispute-against-natera-clears-path-for-radar-st-assay-commercialization 2025-08-29T16:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/orexo-to-share-patent-defense-strategies-following-victory-against-sun-pharmaceutical-in-us-court 2025-08-29T16:56:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orexo-to-share-patent-defense-strategies-following-victory-against-sun-pharmaceutical-in-us-court 2025-08-29T16:56:13+00:00 hourly 0.9 https://trial.medpath.com/news/digitoxin-reduces-death-and-hospitalization-risk-in-advanced-heart-failure-patients 2025-08-29T16:54:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/digitoxin-reduces-death-and-hospitalization-risk-in-advanced-heart-failure-patients 2025-08-29T16:54:05+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-halts-rheumatoid-arthritis-trial-for-nipocalimab-refocuses-on-rare-disease-markets 2025-08-29T16:53:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-halts-rheumatoid-arthritis-trial-for-nipocalimab-refocuses-on-rare-disease-markets 2025-08-29T16:53:20+00:00 hourly 0.9 https://trial.medpath.com/news/mgi-tech-and-jcbio-launch-strategic-partnership-to-advance-multi-omics-research-in-south-korea 2025-08-29T16:52:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mgi-tech-and-jcbio-launch-strategic-partnership-to-advance-multi-omics-research-in-south-korea 2025-08-29T16:52:06+00:00 hourly 0.9 https://trial.medpath.com/news/bicycle-toxin-conjugates-emerge-as-novel-cancer-drug-class-with-promising-clinical-results 2025-08-29T16:51:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bicycle-toxin-conjugates-emerge-as-novel-cancer-drug-class-with-promising-clinical-results 2025-08-29T16:51:41+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-england-to-roll-out-chickenpox-vaccine-in-january-2026-as-part-of-new-mmrv-immunization-program 2025-08-29T16:50:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-england-to-roll-out-chickenpox-vaccine-in-january-2026-as-part-of-new-mmrv-immunization-program 2025-08-29T16:50:14+00:00 hourly 0.9 https://trial.medpath.com/news/everest-medicines-reports-strong-h1-2025-growth-with-advanced-mrna-platform-and-pipeline-expansion 2025-08-29T16:46:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/everest-medicines-reports-strong-h1-2025-growth-with-advanced-mrna-platform-and-pipeline-expansion 2025-08-29T16:46:41+00:00 hourly 0.9 https://trial.medpath.com/news/fda-recommends-enhanced-brain-monitoring-for-alzheimer-s-patients-on-leqembi-following-six-early-deaths 2025-08-29T16:46:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-recommends-enhanced-brain-monitoring-for-alzheimer-s-patients-on-leqembi-following-six-early-deaths 2025-08-29T16:46:22+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-therapeutics-reports-positive-phase-3-results-for-saroglitazar-in-primary-biliary-cholangitis 2025-08-29T16:45:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zydus-therapeutics-reports-positive-phase-3-results-for-saroglitazar-in-primary-biliary-cholangitis 2025-08-29T16:45:20+00:00 hourly 0.9 https://trial.medpath.com/news/fosun-pharma-secures-exclusive-rights-to-accro-s-tyk2-jak1-inhibitor-ac-201-for-greater-china-in-21-8m-deal 2025-08-29T16:45:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fosun-pharma-secures-exclusive-rights-to-accro-s-tyk2-jak1-inhibitor-ac-201-for-greater-china-in-21-8m-deal 2025-08-29T16:45:14+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-s-tazemetostat-receives-orphan-drug-designation-in-japan-for-rare-epithelioid-sarcoma 2025-08-29T16:43:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eisai-s-tazemetostat-receives-orphan-drug-designation-in-japan-for-rare-epithelioid-sarcoma 2025-08-29T16:43:47+00:00 hourly 0.9 https://trial.medpath.com/news/coopervision-s-misight-1-day-becomes-first-myopia-control-contact-lens-approved-in-japan 2025-08-29T16:43:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coopervision-s-misight-1-day-becomes-first-myopia-control-contact-lens-approved-in-japan 2025-08-29T16:43:40+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-shield-blood-test-shows-84-sensitivity-for-colorectal-cancer-detection-in-updated-clinical-data 2025-08-29T15:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-shield-blood-test-shows-84-sensitivity-for-colorectal-cancer-detection-in-updated-clinical-data 2025-08-29T15:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/tetraspecific-antibodies-poised-for-first-fda-approval-by-2029-market-report-reveals 2025-08-29T12:28:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tetraspecific-antibodies-poised-for-first-fda-approval-by-2029-market-report-reveals 2025-08-29T12:28:50+00:00 hourly 0.9 https://trial.medpath.com/news/spica-therapeutics-secures-eur1-million-vlaio-grant-to-advance-anti-cd163-monoclonal-antibody-for-cancer-treatment 2025-08-29T09:24:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spica-therapeutics-secures-eur1-million-vlaio-grant-to-advance-anti-cd163-monoclonal-antibody-for-cancer-treatment 2025-08-29T09:24:31+00:00 hourly 0.9 https://trial.medpath.com/news/rna-polymerase-i-inhibitors-emerge-as-promising-cancer-therapy-with-pindnarulex-leading-clinical-development 2025-08-29T09:20:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rna-polymerase-i-inhibitors-emerge-as-promising-cancer-therapy-with-pindnarulex-leading-clinical-development 2025-08-29T09:20:06+00:00 hourly 0.9 https://trial.medpath.com/news/tasso-and-shemed-partner-to-deliver-personalized-glp-1-weight-loss-treatments-through-at-home-blood-testing 2025-08-29T09:19:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tasso-and-shemed-partner-to-deliver-personalized-glp-1-weight-loss-treatments-through-at-home-blood-testing 2025-08-29T09:19:32+00:00 hourly 0.9 https://trial.medpath.com/news/alphamab-oncology-s-kn026-receives-breakthrough-therapy-designation-for-her2-positive-gastric-cancer-in-china 2025-08-29T09:17:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alphamab-oncology-s-kn026-receives-breakthrough-therapy-designation-for-her2-positive-gastric-cancer-in-china 2025-08-29T09:17:34+00:00 hourly 0.9 https://trial.medpath.com/news/cinclus-pharma-launches-phase-iii-trial-for-novel-gerd-treatment-targeting-european-market 2025-08-29T09:16:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cinclus-pharma-launches-phase-iii-trial-for-novel-gerd-treatment-targeting-european-market 2025-08-29T09:16:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-foresee-s-camcevi-etm-21mg-for-advanced-prostate-cancer-treatment 2025-08-29T09:16:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-foresee-s-camcevi-etm-21mg-for-advanced-prostate-cancer-treatment 2025-08-29T09:16:05+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-discontinues-nipocalimab-combination-therapy-for-rheumatoid-arthritis-after-phase-2a-trial-fails-to-show-added-benefit 2025-08-29T05:19:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-discontinues-nipocalimab-combination-therapy-for-rheumatoid-arthritis-after-phase-2a-trial-fails-to-show-added-benefit 2025-08-29T05:19:39+00:00 hourly 0.9 https://trial.medpath.com/news/arcellx-reports-97-response-rate-in-multiple-myeloma-car-t-trial-targets-2026-commercial-launch 2025-08-29T05:17:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcellx-reports-97-response-rate-in-multiple-myeloma-car-t-trial-targets-2026-commercial-launch 2025-08-29T05:17:11+00:00 hourly 0.9 https://trial.medpath.com/news/entera-bio-to-present-phase-2-osteoporosis-data-and-next-generation-oral-peptide-programs-at-september-2025-conferences 2025-08-29T05:15:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/entera-bio-to-present-phase-2-osteoporosis-data-and-next-generation-oral-peptide-programs-at-september-2025-conferences 2025-08-29T05:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/multidisciplinary-approach-drives-de-escalation-of-breast-cancer-surgery-through-targeted-axillary-management 2025-08-29T03:06:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multidisciplinary-approach-drives-de-escalation-of-breast-cancer-surgery-through-targeted-axillary-management 2025-08-29T03:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/breath-sensor-shows-promise-for-non-invasive-diabetes-detection-in-early-clinical-testing 2025-08-29T02:11:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breath-sensor-shows-promise-for-non-invasive-diabetes-detection-in-early-clinical-testing 2025-08-29T02:11:38+00:00 hourly 0.9 https://trial.medpath.com/news/aavantgarde-reports-positive-phase-1-2-data-for-gene-therapy-aavb-081-in-usher-syndrome-type-1b 2025-08-29T02:10:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aavantgarde-reports-positive-phase-1-2-data-for-gene-therapy-aavb-081-in-usher-syndrome-type-1b 2025-08-29T02:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/psychedelic-medicines-approach-market-entry-as-late-stage-trials-advance 2025-08-29T02:10:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psychedelic-medicines-approach-market-entry-as-late-stage-trials-advance 2025-08-29T02:10:25+00:00 hourly 0.9 https://trial.medpath.com/news/lifileucel-til-therapy-shows-disease-stabilization-in-advanced-head-and-neck-cancer-patients 2025-08-29T02:07:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lifileucel-til-therapy-shows-disease-stabilization-in-advanced-head-and-neck-cancer-patients 2025-08-29T02:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-lipid-nanoparticle-intrabodies-show-promise-against-rickettsial-infections-in-preclinical-studies 2025-08-29T02:06:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrna-lipid-nanoparticle-intrabodies-show-promise-against-rickettsial-infections-in-preclinical-studies 2025-08-29T02:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-confirms-effectiveness-of-cat-allergen-immunotherapy-for-respiratory-allergies 2025-08-29T02:06:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-confirms-effectiveness-of-cat-allergen-immunotherapy-for-respiratory-allergies 2025-08-29T02:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/senate-advances-patent-reform-bill-that-could-revitalize-biotech-innovation-and-diagnostics 2025-08-29T02:06:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senate-advances-patent-reform-bill-that-could-revitalize-biotech-innovation-and-diagnostics 2025-08-29T02:06:32+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-2-study-reports-final-results-for-cd123-targeted-tagraxofusp-in-relapsed-refractory-myelofibrosis 2025-08-29T02:04:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-1-2-study-reports-final-results-for-cd123-targeted-tagraxofusp-in-relapsed-refractory-myelofibrosis 2025-08-29T02:04:12+00:00 hourly 0.9 https://trial.medpath.com/news/gastric-cancer-pipeline-shows-robust-growth-with-220-therapies-in-development-across-200-companies 2025-08-29T02:04:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gastric-cancer-pipeline-shows-robust-growth-with-220-therapies-in-development-across-200-companies 2025-08-29T02:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/novel-selenium-enhanced-exosome-therapy-shows-promise-for-traumatic-cns-injuries 2025-08-29T02:01:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-selenium-enhanced-exosome-therapy-shows-promise-for-traumatic-cns-injuries 2025-08-29T02:01:15+00:00 hourly 0.9 https://trial.medpath.com/news/leukemia-stem-cell-test-shows-superior-prediction-of-aml-relapse-after-transplant 2025-08-28T22:14:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leukemia-stem-cell-test-shows-superior-prediction-of-aml-relapse-after-transplant 2025-08-28T22:14:42+00:00 hourly 0.9